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Metastases are a major cause of morbidity and mortality in breast cancer patients. However, 
current treatments are of limited efficiency because so far very little is known about the 
colonisation of breast cancer cells into the metastatic organs, in particular the brain. It has 
been demonstrated that epithelial to mesenchymal transition (EMT) facilitates tumour 
metastasis with poor prognosis. Moreover, the tumour cell progression might properly be 
dynamic: EMT during invasion and a reversal (MET) during growth of metastasis. 
Consequently, EMT and MET might be a promising target as a possible therapeutic cancer 
treatment. Therefore, the aim of this study was to establish a syngeneic mouse model to 
investigate the colonization at the distant organs, in this case the brain, of metastatic breast 
cancer cells and the impact of EMT and MET on this part during the metastasis process.  
Furthermore, it has been demonstrated that dysregulation of Wnt signalling is associated with 
metastasis and also plays an important role in tumour genesis. Furthermore, the Wnt 
signalling pathway is known to induce EMT and MET and is dysregulated in several cancers, 
with different Wnt molecules being up regulated. If the Wnt pathway is important in cancer 
proliferation and metastasis, inhibitors of Wnts may be valuable for a therapeutic strategy. 
However, because of the multiple receptor combinations and no-central kinase activity the 
inhibition of the Wnt pathway is not trivial. Therefore, to inhibit the secretion of the Wnt-
molecules seemed a very promising strategy. One of the key enzymes during secretion is the 
membrane bound O-acetyltransferase Porcupine. Inhibition of Porcupine leads to the 
inhibition of Wnt palmitoylation and Wnt secretion, and therefore, indirect inhibition of 
receptor binding and activation of the pathway. One Porcupine inhibitor, LGK974, is believed 
to block initiation of tumours through this mechanism suggesting LGK974 is a good 
treatment approach for cancer patients. The second aim of this study was now to investigate 
the inhibitory effects of LGK974, not in tumour initiation, we wanted to study the effect 
during cerebral colonization in vitro and in vivo.  
Finally, we wanted to investigate the role of the immune system, microglia and astrocytes, 
during the invasion of breast cancer in the brain. The established immune-competed mouse 
model provides an opportunity to address this question. Here, the response of microglia and 
astrocytes to lipopolysaccharide (LPS) was used to trigger an immune response.  
Abstract VII 
 
In conclusion, a syngeneic cerebral metastasis mouse model was established and different 
treatment strategies were proved on this. Moreover, the process of colonization of the brain, 
and the impact of the immune systems on in this progress were investigated. 
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1 Introduction 1 
 
1 Introduction 
1.1 Breast cancer and prognosis 
The World Health Organisation (WHO) documented that worldwide over 500.000 women 
die of breast cancer every year 
(http://www.who.int/cancer/detection/breastcancer/en/2015), thus it is the most common 
type of cancer. But not only women, men also suffer from breast cancer. Metastases of 
breast cancer cells are the main cause of death among patients with breast cancer related 
deaths. 10–15% of patients with breast cancer developed metastases within 3 years after 
the first diagnosis (Weigelt et al., 2005). During this time, cancer cells are already 
disseminating and are under dormancy conditions, which mean that pre-metastatic cells 
have already seeded the distant organs and are not active proliferating (Karrison et al., 
1999). In fact, migration of tumour cells away from the primary tumour is generally 
regarded as the first step in metastatic dissemination of breast cancer. Therefore, the basic 
steps of metastasis are - local invasion, intravasation, survival in the circulation, 
extravasation and colonization, which will be described later.  
 
1.2 The role of the environment 
However, the complex process of metastasis formation is not fully understood as of today. 
It is believed that this process is unidirectional, disseminating from the primary tumour 
cancer cell to the distant organ. The English surgeon Stephen Paget proposed first in 1889 
the important role of the microenvironment in metastasis formation. His idea was the “seed 
and soil” theory where cancer cells (=the seed) have an affinity for certain organs (=the 
soil), which offer a compatible microenvironment for tumour growth (Paget, 1989). 
Consequently, metastasis development is not possible when an incompatible “seed and 
soil” exist. This theory was supported and confirmed in several publications (Ribatti et al., 
2006) and believed until today. It was shown that a specific infiltration function of 
metastatic cells is required after disseminating from the primary tumour to make the cells 
organ specific. Furthermore, after the infiltration of a new tissue, cancer cells outcompete 
other cells of this tissue because of a more aggressive form of these cells. Moreover, 
general steps of metastasis might be the same in all types of tumours, however metastasis 
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to other tissues might be more specific and requires different sets of infiltration and 
colonization functions. Also, time periods of metastasis are variable depending on the new 
microenvironment (Nguyen et al., 2009). Therefore, the role of the tumour 
microenvironment for cancer progression and the organ-specific colonization should be 
considered for further investigations. Furthermore, tumour cells are able to create a niche 
by influencing the surrounding stroma cells during metastasis. The function of the stroma 
microenvironment in order to contribute to the breast cancer development needs to be 
addressed both in vivo and in vitro to better understand breast cancer metastasis 
(Bhowmick et al., 2004).  
 
1.3 The special situation of brain metastasis 
Metastasis of the central nervous system (CNS) was demonstrated as a late event with 
limitations for treatment therefore it is an indicator for poor prognosis in diagnosed 
patients (Bos et al., 2009) (Weil et al., 2005). Very little is known about the interactions 
between the brain and the metastatic cells. Moreover, the reason for brain metastasis being 
a late event might be the unusual environment of the brain for cancer cells. Additionally, 
the brain is protected by the Blood-Brain Barrier, which is tighter than the Blood-Organ 
Barrier (BBB). Therefore, extravasation takes longer into the brain than to other organs. 
Both, the unique brain microenvironment and the BBB were hypothesised to influence 
metastatic colonization. Furthermore, the parenchyma of the brain has non-vascular 
stromal basement membrane components. Without these components, cancer cells cannot 
bond to epithelial cells, which is a necessary step for their survival (Carbonell et al., 2009). 
Therefore, neurovasculature was identified as an important partner for metastasis in the 
brain.  
The organ specific immune response of the brain plays an important role in this process. 
Metastasis into the brain induces a neuro-inflammatory response which involves activated 
microglia and astrocytes, similar to what happens during mechanical lesions to the brain 
(Fitzgerald et al., 2008a). Metastatic tumour cells themselves could potentially alter the 
microglia, resulting in a unique interaction. Recently the initial steps of brain colonization 
were studied in vitro, however, when data were compared to the in vivo situation, the 
colonization of breast cancer cells into the brain was different to the in vitro situation. 
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Therefore, investigations of animal models are necessary to understand the complex 
mechanisms how cancer cells colonize the brain (Lorger et al., 2011).  
 
1.4 Available animal models in cancer research 
Fidler et al. showed that cancer cells with a high metastatic potential could be injected 
intravenously leading to spontaneous metastases to distant organs (Fidler and Kripke, 
1977). Another spontaneous mouse model was established from Kamino et al. (Kamino 
and Mohr, 1993). They injected lung carcinoma cells in the artery carotids, which lead to 
brain metastases. However, from the literature we know that not all cell lines are able to 
generate spontaneous metastases. If not depending on a spontaneous metastases model, 
intracranial injection of cancer cells is useful to study the role of the brain 
microenvironment and tumour dissemination. Intracranial Xenograft models were 
established in late 1980 (Kaye et al., 1986), when for the first time glioma cell lines were 
injected intracranially into mice. Over the years, also nude mice and severe combined 
immunodeficient (SCID) mice were compared and tested for intracranial injection of 
cancer cells (Taghian et al., 1993). However, only an immune-competent model is 
applicable for studies of immune-based therapeutic strategies. Moreover syngeneic 
BALB/C mouse models where 4T1 cancer cells were injected in the mammary fatpad, 
4T1-cells showed spontaneous metastatic outgrowth (Aslakson and Miller, 1992a). 
Nevertheless, not all cancer cell lines are able to metastize spontaneously, especially not 
into the brain. Therefore, investigation of a syngeneic mouse model for cerebral metastasis 
is necessary. 
 
1.5 Metastasis of cancer  
The metastatic cascade was investigated over the last decade: Tumour cells spread to 
distant organs and form a new tumour mass, which is described as organ-metastasis. 
Several steps of organ-metastasis make a therapy complex, however, when one of these 
steps is not completed, metastases cannot occur.  
The initial step is that cancer cells manage to enter the circulation were they would taken 
to a specific organ, which depends on the blood flow pattern (Chambers et al., 2000). 
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Cancer cells are able to leave the primary tumour and enter into the body circulation blood 
system. All cancer cells need the ability to survive in the circulation before they can 
extravasate into surrounding tissue of the distant organ. Once cancer cells have been 
seeded their colonization will depend on molecular interaction between cancer cells and 
the environment of the new organ, e.g. the brain. 
 
Fig 1: The metastasis cascade (linear model). 
Formation of the primary tumour, next tumour cells leaving the primary tumour (initiation and 
progression), and attack surrounding vessels (intravasation).Surviving cancer cells circulate and 
arrest in distant organ site before they exit the vessel (extravasation). Followed by seeding and 
dormancy in the brain. Afterwards metastatic cell colonize in the brain and perform 
micrometastasis. Micrometastasis grows to macroscopic metastases in the brain.  
 
Importantly, Chambers et al. described in her study that only 0,02% of injected cancer cells 
were able to colonize in the brain and leading in metastasis (Chambers et al., 2002). This 
was observed when they injected cancer cells in the vene of mice. Moreover, they 
investigate the most critical step for the metastatic cells were the colonization of the distant 
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organ, because the majority of the seeded cells undergo apoptosis, a programmed cell 
death. This findings have a clinically importance.  
Moreover, by the time a primary tumour is detected, it might be already have seeded 
metastatic cells to the to the secondary side. Therefore treatment of the primary tumour or 
the early steps of the metastatic cascade can be successful, however, metastasis might be 
already performed (Fig 2). This knowledge is very important to investigate treatment 
strategies for metastasis. 
  
Fig 2: EMT and MET in metastasis formation in the linear model. EMT induces the 
dissemination of cancer cells. 
Cancer cells intravasate into blood vessels, followed by a transport to distant organs. Cancer cells 
extravasate at secondary sites and can form metastasis through a mesenchymal-epithelial transition 
(MET). 
 
Moreover, it was demonstrated that cancer cells which survived in this foreign 
microenvironment were re-initiate efficient proliferative programs at the metastatic sites 
which leads to metastatic colonization (Valastyan and Weinberg, 2011). For cancer cells to 
adapt to the new environment they need to have the ability for transformation. Several 
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genes, which allow this transformation, were identified as so called metastasis initiation 
genes. These genes can promote epithelial-mesenchymal transition (EMT). EMT is a 
fundamental process that is essential for morphogenesis. Abnormal expression of 
developmental transcription factors such as Twist1, Twist2 and Snail might be able to 
trigger EMT (Nguyen et al., 2009) resulting in increased cancer cell dissemination from 
the primary tumour (Thiery, 2002).  
EMT may mediate the extravasation of cancer cells, which can then disseminate in the 
secondary environment. EMT is critical in the first steps of metastatic formation, however, 
MET is required for colonization of cancer cells revert at some point to their epithelial 
phenotype (Fig 2) (Ramakrishna and Rostomily, 2013).  
The transmembrane protein E-cadherin (Ecad) was identified as a marker of an epithelial 
phenotype. A lack of Ecad decreases cell adhesions and therefore promotes a switch to a 
mesenchymal phenotype, which is considered as a canonical indicator of metastatic EMT 
(Ramakrishna and Rostomily, 2013). The loss of Ecad in cancer cells is associated with 
upregulation of N-cadherin, which is known as the “cadherin switch”. Moreover, Ecad is 
highly expressed in various cancers including breast cancer (Thiery, 2002). Several 
transcription factors are known to regulate the expression of Ecad, e.g. Snail, Snail2 and 
Twist. Twist was found to be overexpressed in breast cancer tissue compared to normal 
breast tissue (Watanabe et al., 2004). A cross talk between cancer cells and the surrounding 
stroma indicates the importance of various genes in EMT (Mani et al., 2008). Summarised, 
EMT might be important in generating the initial metastatic phenotype.  
Many genes or pathways are necessary for the activation of cancer cells from the step of 
dormancy to the formation of brain metastases (Eichler et al., 2011a). It is important to 
understand the process in detail to identify new therapeutic strategies for brain metastasis. 
Thus, the canonical Wnt/ß-catenin pathway was recently identified to play an important 
role in EMT.  
 
1.6 The Wnt signalling pathway and its role in tumour progression 
The Wnt pathway is not only important for cell-cell communication during embryonic 
development and for normal tissue homeostasis. It is also involved in tumorigenesis. 19 
genes of the Wnt family were identified (Nusse, 2005). The canonical Wnt pathway is per 
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definition ß-catenin dependent. Here, Wnt binds to Frizzled (Fz) receptor a seven-
transmembrane molecule with a long amino-terminal extension containing a cystein-rich 
domain. Moreover, Wnt signalling requires also the low-density lipoprotein receptor-
related protein (LRP) family as co-receptor.  
The complex of Wnt, Fz and LRP5/6 recruits dishevelled and axin through the intracellular 
domains of Fz and LRP5/6. Thus, intracellular Fz interacts directly with dishevelled, which 
leads to the stabilisation β-catenin by inhibition of ß-catenin phosphorylation. ß-catenin 
translocates into the nucleus and subsequently binds to transcription factors of the T-cell 
factor/lymphocyte enhancer factor (TCF/LEF) family thereby activating target gene 
expression (Clevers and van de Wetering, 1997). Wnt inhibitory factor-1 and secreted 
Frizzled-Related Proteins can block Wnt signalling by direct binding to Wnt ligands. 
However, other inhibitors of Wnt, e.g. the Dickkopf family are blocking Wnt signalling by 
binding to the co-receptor LRP6 (Semënov et al., 2008). Two other Wnt signalling 
pathways were described within the ß-catenin depended pathway, the planar cell polarity 
(PCP) pathway and the Wnt/Ca
2+ 
pathway. Both non-canonical pathways, Wnt/Ca
2+
 and 
PCP, can be activated by the Wnt ligand Wnt5a (Yamanaka et al., 2002). Furthermore, the 
Wnt/Ca
2+
 pathway can also be activated via Wnt4 and Wnt11, both of which induce an 
intracellular Ca
2+
 release (Kühl et al., 2001).  
In the canonical pathway ß-catenin is involved in the regulation of transcription and also in 
cell adhesion. When Wnt3a or Wnt7a act on their cell-surface receptor, the cytoplasmatic 
ß-catenin translocates into the nucleus after release from the destruction complex. In the 
nucleus ß-catenin binds to TCF/LEF and drives the expression of different genes involved 
in EMT (Clevers and Nusse, 2012). Another important study shows that translocation of β-
catenin in the nucleus leads to break the cell-to-cell adhesion formed by β-catenin and E-
cadherin, as β-catenin was identified as a cadherin-binding protein (Schäfer et al., 2014a). 
 
1.7 Wnt and EMT 
Wnt was recently shown to be involved in EMT. EMT is accompanied with the down 
regulation of Ecad. The transcription factor Snail functions as a potent receptor of Ecad 
expression, which can induce EMT. Snail can act alone or with the Wnt/ß-catenin/ LEF. It 
was demonstrated that Wnt signalling could inhibit Snail phosphorylation and therefore 
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increase Snail protein levels, which is then driving EMT. Therefore, the Wnt signalling 
cascade was identified to activate Snail-driven transcriptional programs and Snail activates 
EMT regulated processes (Yook et al., 2005). In particular, Wnt was demonstrated to 
activate the Wnt/ß-catenin signalling and promote EMT-like phenotypes in breast cancer 
cells (Wu et al., 2012). These studies focused on ß-catenin. However, not many studies 
investigated the role of Wnt ligands on EMT so far. Nonetheless, EMT has been shown to 
be induced by Wnt in colon cancer cells. This was investigated in human colon cancer 
tissue, with focus on a specific member, Wnt3a. Low levels of Ecad and higher levels of 
Vimentin and ß-catenin were found in the Wnt3a expression group compared to the control 
group with no expression of Wnt. Additionally, Wnt3a is able to promote the expression of 
the EMT inducing transcription factors, e.g. Snail (Qi et al., 2014). These findings also 
confirm the importance of Wnt signalling and EMT for the microenvironment.  
Wnt genes are expressed in healthy tissues, including the breast. However, diseased breasts 
showed dysregulated expression of Wnt genes (Huguet et al., 1994a). Moreover, Wnt5a 
was shown to be overexpressed in many human cancers (Pukrop and Binder, 2008) and 
Wnt7a was also found to be overexpressed in breast cancers (Kirikoshi and Katoh, 2002). 
Wnt5a was not only expressed in cancer cells, but also in macrophages at the invasive 
front of the tumour. Therefore, Wnt genes might be involved in regulating tumour cell 
invasion induced by macrophages, especially Wnt5a (Pukrop et al., 2006).  
 
1.8 Wnt signalling during cerebral metastasis 
The Wnt pathway was identified in breast cancer patients as a contributing factor to 
facilitate breast cancer metastize into the brain (Smid et al., 2008). The importance of 
WNT signalling for breast cancer metastasis, especially into the brain was demonstrated in 
our group (Klemm et al., 2011). Importantly, not only the classical WNT/β-catenin 
pathway was shown to be involved, also the β-catenin-independent pathway was 
demonstrated to be relevant in breast cancer progression (Klemm et al., 2011). 
Furthermore it we showed that the Wnt pathway needs to be activated during microglia-
induced invasion (Pukrop et al., 2010a). On the other hand, Wnt genes are act on microglia 
and are involved in tissue protection in the central nervous system (CNS) (Halleskog and 
Schulte, 2013). Thus, Wnts are regulated by pro- and anti-inflammatory mechanisms, 
which also indicate the dual role of microglia in health and disease (Hanisch and 
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Kettenmann, 2007). Epithelial cells are capable of inducing a damage response following 
lesions to the brain and that microglia can have a protecting effect on this response 
inducing apoptosis (Chuang et al., 2013).  
In case of infiltration of the malignant cells into the adjacent brain parenchyma, the 
induction of apoptosis as a damage response is not efficient. Therefore, cancer cells can 
use the glial interaction to succeed in infiltrating the adjacent brain parenchyma. The exact 
mechanism how tumour cells can avoid this apoptotic step is not fully understood. 
However, Wnt signalling is involved in tumour progression rather than in tumour apoptosis 
and this is process is mediated by glia cells (Chuang et al., 2013). Further studies are 
required to identify the role of Wnts in the regulation of microglia and the CNS immune 
response and the role of Wnt in colonization of the distant organs, especially the brain. 
 
1.9 Wnt secretion and inhibition of Wnt secretion 
If the Wnt pathway is important in cancer proliferation and spread, the inhibition/the 
modulation of Wnts may be a good target for therapeutic strategies. However, 
manipulation at the receptor-level is not trivial because the receptor complexes are very 
heterogenous and therefore Wnts are not a clear target. The same is true for inhibiting the 
activating kinase activity. Since, the canonical Wnt pathway is based on the inhibition of a 
central kinase (GSK3ß), this simple strategy is also not constructive. Modification of the 
Wnt secretion seems a very rational treatment concept though. However, the mechanisms 
of Wnt secretion are not fully understood. A crucial step for Wnt secretions is the 
palmitoylation of Wnt protein, which is mediated by the enzyme Porcupine. This key 
enzyme belongs to the family of membrane-bound O-acetyltransferase (MBOAT) and is 
located in the membrane of the endoplasmic reticulum (Siegfried et al., 1994). Inhibition 
of Porcupine leads to the prevention of Wnt palmitoylation and thereby Wnt secretion 
(Kurayoshi et al., 2007). These findings and the knowledge of the influence on Wnt in 
tumour initiation and metastasis formation leads to the idea that inhibition of Porcupine in 
order to block Wnt secretion might have a beneficial effect on cancer treatment. 
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Fig 3: Porcupine is essential for Wnt secretion. 
The acyltransferase Porcupine in the endoplasmic reticulum is required for palmitoylation of Wnt 
proteins and therefore necessary for Wnt secretion (Mikels and Nusse, 2006). 
 
The idea of a promising inhibitory effect of Porcupine to block Wnt secretion was 
followed up over the last years.  
The important role of Porcupine for cell proliferation and activation of the Wnt pathway 
was shown in gastric cancer exhibiting high expression levels of Porcupine. By using a 
palmitoyltransferase inhibitor specific for Porcupine (inhibitors of Wnt production (IWP-
2)), the cell proliferation, migration and invasion was inhibited in gastric cancer cells. 
Furthermore, the Wnt/β-catenin signalling pathway activity was downregulated by IWP-2 
(MO et al., 2013). Chen and colleagues showed the ability of IWP compounds to 
selectively target a member of the MBOAT family of acetyltransferases (Chen et al., 
2009).  
Another Porcupine inhibitor Wnt-C57 (patented by Novartis), a small-molecule inhibitor, 
was shown to block Wnt palmitoylation, Wnt interaction with the carrier protein Wingless 
and the Wnt secretion. Wnt driven tumours growth was decreased by using Wnt-C57 in 
mice (Proffitt et al., 2013). The inhibitory effect of Wnt-C57 was evaluated for all ß-
catenin activating Wnts and in all noncanonical Wnts. Summarising, the Porcupine 
inhibitor, IWP-2, is highly potent and specific in inhibiting Wnt signalling in vitro (Chen et 
al., 2009) (Dodge et al., 2012). WNT-C59 was found to be effective in a Wnt-dependent 
mouse tumour model (Proffitt et al., 2013). However, pharmacological Wnt inhibitors 
result in high toxicity and thus have adverse effects at high doses (Chen et al., 2009). 
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A new and more specific Porcupine inhibitor LGK974 is believed to block tumour 
progression through inhibition of the Wnt signalling pathway. LGK974 was shown to be 
well tolerated at the effective doses (Liu et al., 2013a). Therefore, Porcupine inhibition 
seems a bona fide target for cancer treatment. Importantly, in a human based study tumour 
growth was decreased at well-tolerated doses of LGK974. These results supported the use 
of LGK974 for clinical use for the treatment of Wnt driven tumours, and Novartis began to 
use LGK974 in early-phase clinical trials. The study included patients with malignancies 
dependent on Wnt ligands, (https://clinicaltrials.gov/show/NCT01351103), however, the 
results from this study have not been published yet.  
 
Fig 4: Inhibition of Porcupine.  
LGK974 inhibit Porcupine and therefore palmitoylation of Wnt proteins and Wnt secretion 
(http://www.novartisoncology.com/ct/pipelineDetails?compound=LGK974&diseaseAcr=BC.) 
 
1.10 Immune response on tumour cell invasion 
The role of the tumour microenvironment has been frequently shown to be important in 
cancer. The malignancy can be suppressed by the immune response, however, most 
tumours are able to overcome this process and the metastatic potential can be increased, 
which was shown in mouse models (Joyce and Pollard, 2009). Furthermore, peripheral 
macrophages can promote the invasiveness of cancer cells. Usually, one role of 
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macrophages is to destroy malignant cells, however, it has been shown that they are able to 
secrete factors necessary for cancer progression. Activation of tumour-associated 
macrophages (TAM) could result in a release of a vast diversity of growth factors, 
proteolytic enzymes, cytokines, and inflammatory mediators that may facilitate cancer 
metastasis (Chen et al., 2005). Additionally, tumour cells are able to attract and manipulate 
cells of the immune system, e.g. the TAM. Therefore, immune cells assist in tumour 
progression. This was confirmed when invasion inducing macrophages were blocked by 
using a Wnt inhibitor leading in a decrease or tumour progression (Pukrop et al., 2006). 
Infiltrating TAM were detected at the invasive front of mammary tumours in human 
samples. The environment of the brain reacts differently compared to other organs and the 
immune response of microglia might be different compared to the response of 
macrophages. Furthermore, astrocytes and microglia were highly activated after seeding of 
pre-metastatic tumour cells in the brain parenchyma (Lorger and Felding-Habermann, 
2010).  
 
1.11 The role of microglia and astrocytes in malignancies 
Microglia cells are resident mononuclear phagocytes that play a fundamental role in the 
protection of normal tissue homeostasis in the central nervous system. Under normal 
conditions, the immune response of microglia in the brain is mainly the repair of the CNS 
and the activation of microglia is normally reversible, hyperactivation of microglia often 
leads to neurotoxic effects (Nakamura, 2002). Microglia and astrocytes were activated in 
response to proinflammatory stimuli. Astrocytes are identified by the intracellulary 
expressed cell type-specific marker glial fibrillary acidic protein (GFAP), microglia by cell 
surface Fc receptors (CSFR) (Kennedy et al., 1980). Astrocytes play an important role in 
lending support of the Blood-Brain-Barrier (BBB) (Abbott et al., 2006) and regulating the 
immune response of the CNS. However, it was shown that astrocytes become activated in 
response to tumour progression, and the size of the tumour is directly correlated to the 
number of activated astrocytes (Langley et al., 2009). Additionally, microglia cells are 
regulated by the macrophage growth factor colony stimulating factor-1 (CSF1) which 
signals via the transmembrane tyrosine kinase receptor (CSFR1). CSFR1 was shown to be 
also upregulated in injured neurons. CSF1 upregulation also correlates with 
neurodegeneration and neuroinflammation (Luo et al., 2013). Furthermore, dysregulation 
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of microglia cells played a central role in cancer (Saijo and Glass, 2011). As the function 
of microglia cells can be protective but also cytotoxic (Zhang and Olsson, 1997), microglia 
might influence tumour cell survival. Moreover, microglia are extremely sensitive to 
changes in the brain microenvironment, which can be an exciting mechanism (Barron, 
1995). For experimental design, LPS can induce activations of microglia.  
Micrometastatic breast cancer cells are changing the brain microenvironment, which can 
lead to metastatic progression. The glia cell reaction induces an altered brain 
microenvironment by e.g. by the formation of a surrounding wall. This might provide the 
basis for glia-tumour cell interactions thereby influencing metastatic progression. The 
metastatic tumours cells might change glia cells by unknown mechanisms (Fitzgerald et 
al., 2008b). Furthermore, it is possible that microglia cells reduce the production of 
cytotoxic factors after contact with tumour cells allowing tumour cells to colonize. At the 
onset of brain metastases there is a balance between the protective and cytotoxic effect of 
microglia cells. This effect is likely to be influenced by signals of the seeded pre-metastatic 
tumour cells, including different factors (He et al., 2006a). A better understanding of the 
interactions between tumour cells, glia cells and epithelial cells could help to develop new 
therapeutic approaches. 
 
1.12 Therapeutic approaches and animal models of cerebral metastasis 
It is obvious that the brain microenvironment plays an important role in the formation of 
metastases. Furthermore, the role of the brain environment in order of breast cancer 
metastasis is different in comparison to other organs. The special environment of the brain, 
which includes the BBB and specific immune responses of the CNS, makes it a unique 
organ. The BBB is composed of a layer of endothelial cells and astrocytes, making the 
BBB impermeable for most cells. Moreover, the BBB can prevent the entrance of 
leukocytes and immunoglobulins from the blood. However, once tumour cells attack the 
BBB, the endothelial cells of the BBB and tumour cells can form a blood-tumour barrier 
(Fidler, 2011), which can lead to colonisation of tumour cells and therefore to metastasis 
formation. The leakage of the most cytotoxic agents through the BBB is usually limited, 
and treatments e.g. chemotherapy, are therefore complicated (Steeg et al., 2011). On the 
other hand, when the interaction of astrocytes and endothelial cells was disrupted the 
impermeability of the BBB seemed to be directly related to the uptake of chemotherapeutic 
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agents. Furthermore, the unique brain microenvironment impedes anti-tumour therapies, 
therefore it is challenging to develop efficient strategies to target brain metastasis (Eichler 
et al., 2011b).  
To investigate new therapeutic strategies and to understand all of the steps involved in this 
process, animal models for brain metastasis that are able to mimic the human disease are 
necessary. Unfortunately, progress in this field of research is still limited by the few 
spontaneous models available. The chance for metastatic cells to reach the brain is not 
100% given because - unlike epithelial cancers - metastatic cells often die before the brain 
is colonized. Furthermore, while the ability of tumour growth in immune-deficient mouse 
models gives extremely valuable results to understand tumour biology, the assistance of 
the immune cells and the lack of immune-signalling- which play an important role in brain 
metastases- cannot be analysed in these models 
(http://www.ncbi.nlm.nih.gov/books/NBK100378/). Therefore, a syngeneic mouse mode is 
more suitable. 
Furthermore, a combined treatment involving the stimulation of the immune system by e.g. 
LPS can further help to investigate the role of immune response on tumour colonization. It 
has been shown in vitro that LPS-activated microglia cells can destroy some metastatic 
cancer cells (He et al., 2006a). Interestingly, LPS was also found to be neuroprotective and 
reduced cell death (Bingham et al., 2011).  
In a brain slice model it was shown that microglia interact with tumour cells and thereby 
enhance the invasiveness of breast cancer cells. Moreover, a dense inflammatory infiltrate 
consisting of active microglia around the tumour mass was observed. Similar results were 
shown by He et al. (2006), suggesting that the degeneration of neurons can activate 
microglia, however, the link between neuronal deaths or degeneration and microglia 
activation could not be made clearly. Later, our group demonstrated that the Wnt pathway 
plays an important role in macrophage-induced tumour invasion in primary tumours 
(Pukrop et al., 2006). This was also confirmed in the distant organ, the brain, where Wnt 
inhibition leads to reduced tumour invasion in the brain slice model (Pukrop et al., 2006). 
In order to prove the proinvasive effect of microglia and the important role of Wnt 
signalling during this event, Han-Ning Chuang triggered a proinflammartory response by 
using LPS in brain slices after adding single tumour cells. Then she analysed gene 
expression patterns and found Wnt signalling to be one of the most misregulated pathways. 
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Furthermore Han-Ning demonstrated that LPS affects several Wnt related genes in 
microglia. Another regulated pathway was the Toll-Like Receptor (TLR) pathway. Also it 
was shown that TLR4 activation affected several Wnt related genes in microglia.  
In this study we built up on these previous results and we aimed to further define the role 
of the immune system and also the importance of Wnt signalling on tumour colonization. 
In order to elaborate this in greater detail the goals of this study were: 
1) To establish a syngeneic mouse model to investigate the colonization behaviour, the 
morphological metastatic patterns and analysed Wnt signalling and EMT-markers. EMT 
marker expression might be critical for tumour invasion. Therefore, we characterized 
suitable cancer cell lines and focused on epithelial and mesenchymal markers of all 
analysed cancer cell lines and investigated their colonization behaviour. 
2) To investigate whether Wnt secretion is important for colonization of the CNS and 
therefore might be a good therapeutic target. For this proposes, we tested the Porcupine 
inhibitor LGK974, which was suggested to block Wnt secretion and therefore tumour 
invasion.  
3) To further elaborate on several exciting findings that we had made in our group by in 
vitro studies on the role of microglia on tumour colonization. We wanted to transfer these 
in vitro findings to the established syngeneic cerebral metastasis mouse model, as this 
model is physiologically more similar to the human situation. 
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2 Materials und Methods  
2.1 Materials 
2.1.1 Biological material 
2.1.1.1 Cell Lines 
All cell lines used in this study are listed in Tab 1. 
Tab 1: Cancer Cell lines 
Cell line Cell type Characteristics Obtained 
from 



































a cell line 



































2 Materials und Methods 17 
 
2.1.2 Cell culture media and additives 
All media and additives used are listed in Tab 2. 
Tab 2: Cell culture media and additives 
Product Company 
DMEM medium Biochrim (Berlin) 
Fetal calf serum (FCS) Sigma (Munich) 
Penicillin/streptomycin (P/S) Biochrom (Berlin) 
RPMI-1640 medium PAA (Cölbe) 
Trysin Biochrome (Berlin) 
 
  
2 Materials und Methods 18 
 
2.1.3 Chemicals, Commercial kits and standards 
All chemicals, commercial kits and standards used are listed in Tab 3. 
 
Tab 3: Chemicals, Commercial kits and standards 
Product Company 
„Cell Proliferation Reagent“ WST-1 Roche Applied Science, (Mannheim)  
DNA ladder 100kb Fermentas (St. Leon-Rot) 
Extracellular matrix gel (ECM) Trevigen, R&D, (Wiesbaden-Nordenstadt) 
High Pure RNA Isolation kit Roche (Grenzach-Wyhlen) 
iScript cDNA synthesis kit Bio-Rad (München) 
Laemmli loading buffer, non-reducing, 4x bioPLUS (Mol, Belgium) 
Laemmli loading buffer Roti®-Load 1, 
reducing, 4x 
Roth (Karlsruhe) 
LGK974 powder Active Biochemicals (Hong Kong) 
LPS from Escherichia coli Enzo Life Sciences (Lörrach) 
Phenol/chloroform/isoamyl alcohol Roth (Karlsruhe) 
Phosphatase inhibitor PhosSTOP, 10x Roche (Grenzach-Wyhlen) 
Ponceau S Merck (Darmstadt) 
SYBR green Roche (Mannheim) 
MTT for MTT assay Sigma (München) 
100xProteaseinhibitor Cocktail Sigma (München) 
Phosphatase inhibitor “PhosStop” Roche (Mannheim) 
4x loading buffer "Roti-Load 1"  Roth (Karlsruhe) 
Precision Dual Color Protein Standard Biorad (München) 
Protein loading buffer bioPLUS Bio-world (USA)  
Hybond-C Extra membrane Amersham Biosciences (Freiburg) 
Ponceau S solution  Omnilab Krannich (Göttingen) 
Dnase I  Roche (Mannheim) 
"ECL Plus"  GE Healthcare (Freiburg) 
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2.1.4 Antibodies  
The antibodies used for Western Blot analyses are listed in Tab 4. 
Tab 4: Antibodies 
Product Host species Application  Company 
Wnt5a rat 1:2000 R&D (MAB645) 
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2.1.5 Oligonucleotides 
All used Oligonucleotides directed against mouse cDNA are listed in Tab 5. 
 
Tab 5: Oligonucleotides 
Name Sequence (5´-3´) 
mm-GAPDH fw CATCTTGGGCTACACTGAG 
mm-GAPDH rv CTGTAGCCGTATTCATTGTC) 
mm-RNA 18s fw GTAACCCGTTGAACC CCATT 
mm-RNA 18s rv  CCAT CCAATCGGTAG TAGCG 
mm-CSF1 fw GCGCTTTAAAGACAACACCC 
mm-CSF1 rv  ATGGAAAGTTCGGACACAGG 
mm-Vimentin fw CGGCTGCGAGAGAAATTGC 
mm-Vimentin rv  CCACTTTCCGTTCAAGGTCAAG 
mm-CSF1R fw  CACCATCCACTTGTATGTC 
mm-CSF1R rv  CTCAACCACTGTCACCTC 
mm-Ecad fw GGATATTAATGACAACGCTCC 
mm-Ecad rv  GCATTGACCTCATTCTCAG 
mm-CK8 fw ATGAACAAGGTGGAACTAGAG 
mm-CK8 rv  ATCTCCTCTTCATGGATCTG 
mm-CK19 fw CCTACAGATTGACAATGCTC 
mm-CK19 rv  GTGTTCTGTCTCAAACTTGG 
mm-GFAP fw AACCTGGCTGCGTATAGAC 
mm-GFAP rv  CCAGCGATTCAACCTTTCTC 
h/mmTwist2 fw TACATAGACTTCCTCTACCAGG 
h/mmTwist2 rv GGTCATCTTATTGTCCATCTCG 
mm Zeb2 fw CCACGATCCAGACCACAATTA 
mm Zeb2 rv TACTCTTCGATGCTCACTGC 
mm Snail1 fw TGAAGATGCACATCCGAAGC 
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Name Sequence (5´-3´) 
mm Snail1 rv CAGTGGGAGCAGGAGAATG 
mm-Wnt5a fw TTACACAACAATGAAGCAGG 
mm-Wnt5a rv ACACTCCATGACACTTACAG 
mm-LEF1 fw TCATCCAGCTATTGTAACACCT 
mm-LEF1 rv TGCTCCTTTCTCTGTTCGT 
mm-Zeb1 fw CAGTATTACCAGGAGGCA 
mm-Zeb1 rv CACACTCGTTGTCTTTCAC 
mm-ßcat fw TACGAGCACATCAGGACAC 
mm-ßcat rv CCAGTACACCCTTCTACTATCTC 
mm-Wnt6 fw GGTTCGAGAATGTCAGTTCC 
mm-Wnt6 rv ATTGCAAACACGAAAGCTG 
mm-Wnt5b fw GAGAAGAACTTTGCCAAGG 
mm-Wnt5b rv GACATCAGCCATCTTATACAC 
mm-Porc fw CTTGTCAAAGCGTTGTCTG 
mm-Porc rv CAAGTTTAAGGCTCGTACC 
mm-Wnt3a fw ATCTTTGGCCCTGTTCTG 
mm-Wnt3a rv TCACTGCGAAAGCTACTC 
mm-Twist1 fw GTACATCGACTTCCTGTACCA 
mm-Twist1 rv TTGCCATCTTGGAGTCCAG 
mm-Wnt7a fw CAGTTTCAGTTCCGAAATGG 
mm-Wnt7a rv GATAATCGCATAGGTGAAGG 
mm-Wnt10a fw AGATCTGATTGACATTCCTCC 
mm-Wnt10a rv TGAGCTAGGAACAGAAAGAG 
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2.1.6 Equipment 
All lab equipment used is listed in Tab 6. 
 
Tab 6: Equipment 
Product Company 
Analytical balance, Sartorius excellence Sartorius (GöttingenFC) 
Anatomical tweezers  Carl Teufel GmbH & Co (Liptingen) 
Autoclave Varioklav Thermo Scientific (Bonn) 
Axiovert 200M fluorescence microscope Zeiss (Jena) 
Bioanalyzer 2100 Agilent (Santa Clara, USA) 
Biolumineszenz Imager (VisiLuxx) Visitron Systems (Puchheim) 
Camera EOS 600D Canon 
CO2 incubator CB150 Binder (Tuttlingen) 
Embedding Center EG1160 Leica Microsystems (Wetzlar) 
Foreign Body tweezers Carl Teufel GmbH & Co (Liptingen) 
Gavage 0,8Ø   
Hamilton Microliter Syringes, 10μl 
(26s/51/2)  
Hamilton (Bonaduz, Schweiz) 
Iridectomy scissors Carl Teufel GmbH & Co (Liptingen) 
Microsurgery tweezers Carl Teufel GmbH & Co (Liptingen) 
Microtome Leica RM 2165 Leica (Wetzlar) 
Microwave Powerwave; Braun 
MilliQ water purification system Millipore (Schwalbach) 
NanoDrop ND-1000 spectrophotometer Peqlab (Erlangen) 
Neubauer Improved cell counting chamber LO Laboroptik (Friedrichsdorf) 
PH meter 761 Calimatic Knick Elektronische Messgeräte (Berlin) 
Pipetboy Integra biosciences (Femwald) 
Refrigerated microfuge SIGMA 1-15K Sigma Laborzentrifugen (Osterode am 
Harz) 
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Product Company 
ScanScopeXT Aperio/Leica (Wetzlar) 
Semi-enclosed Benchtop Tissue Processor 
TP1020 
Leica Microsystems (Wetzlar) 
Steamer Braun 
Stereotactic apparatus model 900 Kopf Instruments (Tujunga, California) 
Surgical lighting Hanaulux 2208 Medap, (Feldkirch) 
Sutures Seralon 7/0  DCV- INstrumente (Seitingen- Oberflacht) 
Thermal cycler T3000 Biometra (Göttingen) 
Vascular clamp Fine Science Tools (Heidelberg)  
Vortex shaker Genius 3 IKA Lab equipment (Staufen) 
Water bath Köttermann (Uetze, Hänigsen) 
Mini-gel electrophoresis system Biometra (Göttingen) 
Blotting system  Biometra (Göttingen) 
LAS 4000 Imager Fuji Film / GE Healthcare, (Freiburg) 
HT 7900 Real-Time PCR system Applied Biosystems, (Darmstadt) 
"Hybond-C Extra"  Amersham Biosciences, (Freiburg)  
"GB33Whatman paper B003"  Heinemann laboratory technology 
(Duderstadt) 
Mikropistill Faust (Schaffhausen, Scheiz) 
Motor for Mikro-Pistill Faust (Schaffhausen, Scheiz) 
Inverted microscope Axiovert 200M Zeiss (Göttingen) 
Microscope Leica DMLB Colorview Leica (Wetzlar) 
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2.1.7 Anaesthetics agent and antalgesic 
All anaesthetics agents an antalgesic used are listed in Tab 7. 
Tab 7: Anaesthetics agent and antalgesic 
Medication Company Dose 
Antisedan® 
(Atipamezolhydrochlorid)  




Intervent 85 mg kg-1 Bodyweight 
Rimadyl®  Pfizer 5 mg kg-1 Bodyweight 
Domitor® 
(Xylazinhydrochlorid)  




2.2.1 Cell culture methods 
2.2.1.1 Maintenance of cells 
Cells were grown at 37°C and 5% CO2 in a humidified incubator. Cells were first washed 
with 5ml PBS, separated by incubation in 1ml Trypsin for up to 15 min and splitted in a 
ratio of 1:10 for passage. In case of BAL17, the cells were centrifuged, washed and then 
splitted 1:10 daily. Contamination with Mycoplasma was tested frequently for all cell 
lines. To store cells over a longer period, they were frozen in DMSO +90% FCS and stored 
at -150°C. 
 
2.2.1.2 LGK974 preparation 
2-[5-Methyl-6-(2-methyl-4-pyridyl)-3-pyridyl]-N-(5-pyrazin-2-yl-2-pyridyl)acetamide 
(LGK974) was delivered as a powder with a molecular weight of 396.44g/mol. Stock 
solution of 10mM were prepared (3,96mg LGK974/mlDMSO) and frozen. For each 
experiment performed with LGK974, stock solution were used and diluted. 
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2.2.1.3 MTT assay 
Cell viability was measured by MTT assay (Mosmann, 1983). Treatment with or without 
inhibitor was tested to compare the viability of the cells. The assay is based on the 
conversion of the water-soluble, yellow tetrazolium salt 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromid (MTT) to an insoluble, purple formazan. This reduction is 
mediated by NAD(P)H-dependent enzymes in the endoplasmic reticulum (Berridge and 
Tan, 1992) and therefore highlights apoptotic or necrotic cells which have an altered cell 
metabolism. 
For the MTT assay, 2x10
4
 cells of E0771LG, 4x10
4
 cells of 4T1, 4x10
4 
cells of 410.4, 
1x10
5
 human Mɸ per well were seeded in triplicate in a 24-well-plate and incubated with 
the LGK974 inhibitor at the indicated concentrations and time periods. Afterwards, the 
cells were incubated with 500μl equivalent culture medium +10% MTT (stock solution: 
5mg/ml) for 4h at 37°C and 5% CO2. The medium was aspired and cells lysed in 500μl 5% 
formic acid containing 63% isopropanol and 32% DMSO. The extinction at 540nm was 
measured in triplicate using a photometer and was normalized to the extinction of the 
untreated control. 
 
2.2.1.4 WST-1 test 
The WST-1-test measured the viability of cells. The principle of the reaction is the 
conversion of the tetrazolium salt WST-1 by succinate-tetrazolium reductase to formazan. 
The measured change in colour of the sample from light red to dark red is proportional to 
the amount of enzyme in the culture that will be used. For the WST-test 2,5x10
4
 microglia 
cells per well were seeded in triplicate in a 24-well-plate and incubated with the LGK974 
inhibitors at the indicated concentrations and time periods. Subsequently, the cells were 
incubated with 500μl culture medium for 24 hours before incubation in 500µl and 50µl 
WST 1 substrate for 2h at 37°C and 5% CO2. The extinction at 540nm was measured in 
triplicate using a photometer and compared to the extinction of the untreated control.  
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2.2.1.5 xCelligence 
As an additional method for real-time monitoring of cell viability and proliferation 
measurements the xCelligence system (RTCA DP Analyzer, Roche), an electronic 
impedance-based cell sensing measurement system, was used. Here, 5x10
3
 cells of 410.4, 
2,5x10
3
 cells of 4T1 and 2x10
3
 cells of E0771LG, respectively, were seeded per well in 
E16 plates (Roche) and stimulated with concentration of 2.5µM and 5µM of LGK974 for 
48h. The bottom of these wells is covered with a gold microelectrode, therefore, changes in 
electrical impedance can be measured when the cells attach and spread on the electrode 
surface. Consequently, cell growth and spreading result in increased impedance while 
detachment or rounding up of cells lead to a reduction. With this method, which is 
comparable to the MTT-assay and as well to the WST-test, the cell index is determined. 
 
2.2.1.6 Cell invasion assay (modified Boyden chamber) 
The microinvasion assay was performed with a modified Boyden chamber system, which 
has been described previously (Hagemann et al., 2004). The membrane consists of 
polycarbonate (pore diameter: 10μm, Pieper Filter) and was coated with 1:4 dilution 
extracellular matrigel (ECM) in serum-free RPMI-1640 medium. Cancer cell invasion was 
determined by counting the cancer cells in the lower chamber that invaded through the 
artificial basement membrane. In case of 410.4 cells, cells were cocultured with microglia. 
Cells were performed with cell culture inserts (BD, Heidelberg, Germany) in the upper 
chamber, without cell-to-cell contact to the cancer cells. The experiments were performed 
twice, once with pre-stimulation once without 24h pre-stimulation with LGK974. For all 
experiments 1x10
5 
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Fig 5: Schema of Microinvasion assay. 
The invasive cancer cells were seeded in the upper well of the chamber. In case of 410.4, microglia 
cells were added. After 96h the numbers of invasive cells, which had degraded the ECM gel to the 
lower wells, were counted und compared with unstimulated cancer cells. 
 
2.2.2 Protein biochemistry 
2.2.2.1 Protein Isolation from cells 
For the isolation of total protein the generation of lysates, all used cell lines were seeded in 
6-well plates in a concentration of 1x 10
6
 cells per well. The possibility to adhere was 
given for at least for 4hours and then incubated with or without stimulation. After the 
indicated time points cells were washed once with cold PBS. Afterwards 100μl RIPA lysis 
buffer was added before cells were detached from the well with a cell scraper on ice, and 
transferred into 1,5ml tubes. After an incubation of 10-20min, lysates were centrifuged for 
5min at 20.000xg and 4°C to pellet cell debris and DNA. Supernatants were collected in 
1,5ml tubes and stored at -20°C. 
 
RIPA lysis buffer:  Tris, pH 7,2   50 mM  
     NaCl    150 mM  
     SDS     0,1%  
     Na-deoxycholat   0,55 % 
     Triton X-100  1%  
 
For protein lysates from cells, protease inhibitors (“100xProteaseinhibitor Cocktail”) as 
well as phosphatase inhibitors (“PhosStop”) were added to the lysis buffer according to the 
manufacturer’s instructions. 
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2.2.2.2 Protein quantification by Lowry assay 
Protein concentrations were determined by Lowry assay (DC protein assay, Bio-Rad) 
using a BSA standard curve. According to the manufacturer’s instructions all samples were 
diluted 1:10 in 10μl ddH2O. The Lowry assay is based on the colorimetric detection of 
copper (I) ions, which bind to Bicinchoninsäure (BCA). In the presence of proteins copper 
(II) ions are reduced to copper (I) in a concentration-dependent manner. The violet product 
was measured in a photometer at 750nm (Lowry et al., 1951). 
 
2.2.2.3 SDS Polyacrylamidgelelectrophoresis (SDS-PAGE) 
For detecting proteins in cell lysates by Western blot, SDS-PAGE (Laemmli, 1970) was 
used for size fractionation. Therefore, proteins pass through a polyacrylamide gel with two 
layers within an electric field. First the stacking gel (neutral pH) collects the proteins in 
one band before the resolving gel (basic pH) separates them. In order to allow their 
separation in an electric field, the protein lysate were mixed with the anionic surfactant 
SDS. This surfactant binds proteins proportional to their size based on their negative 
charges. Prior to electrophoresis, protein lysates were incubated with 4x loading buffer 
"Roti-Load 1" and boiled for 5min at 95°C to denature the proteins. The loading buffer 
contains ß-mercaptoethanol, which reduces the protein disulfide bonds. Also, the SDS 
binds to proteins and applying negative charge in proportion to their mass. The 
electrophoresis was performed in a vertical mini-gel electrophoresis system (Biometra) 
using Tris-Glycine running buffer. The focusing of proteins in the stacking gel was carried 
out for 30min at 90V, the subsequent separation in the resolving gel for approximately 
90min at 130V. For the determination of the protein sizes a standard was applied 
("Precision Dual Colour Protein Standard"). 
In the case of Wnt5a protein PAGE was performed under non-denaturing conditions with 
β-mercaptoethanol-free loading buffer (bioPLUS).  
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5% Stacking gel:   Tris + 2% SDS (1,5 M; pH 6,8)   630μl  
     Acrylamid/Bisacrylamid 30%  830μl  
     APS (10%)      50μl  
     TEMED      5μl  
     H2O (bidest.)     3,45ml  
 
10% Separating gel:     Tris + 2% SDS (1,5 M; pH 8,8)   5ml  
     Acrylamid/Bisacrylamid 30%   6,7ml  
     APS (10%)      200μl  
     TEMED      20μl  
     H2O (bidest.)     7,9ml 
 
 
1× Electrophoresis buffer: Tris      3g 
     Glycin    14,4g 
SDS     1g    
 H2O (bidest.)   ad 1l 
 
 
2.2.2.4 Western Blot 
Western blot analyses were used to transfer proteins from a gel onto a nitrocellulose 
membrane. Subsequently proteins were detected with antibodies (Towbin et al., 1979). A 
semi-dry blotting system was used for all proteins. 
The nitrocellulose membrane "Hybond-C Extra" (Amersham Biosciences) and 
"GB33Whatman paper B003" (Heinemann laboratory technology), were equilibrated for 
5min in transfer buffer before the membrane was put on three “Whatman paper”.  
Afterwards, the polyacrylamide gel was washed with transfer buffer and placed on the 
nitrocellulose membrane, and topped by three layers of “Whatman paper” soaked with 
transfer buffer "GB33 Whatman FilterB003". Then, the blot chamber was closed and the 
protein transfer was carried out at 10V for 75min. To verify a successful transfer, the 
nitrocellulose membrane was stained with Ponceau S solution, which stains all proteins. To 
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detect specific proteins, the nitrocellulose membrane was incubated with antibodies 
specific for the respective proteins. Therefore, the membrane was incubated for 1h in 
blocking solution at room temperature to prevent non-specific binding. Afterwards, the 
primary antibody was diluted according to the manufacturer's instructions in block solution 
and incubated with the membrane overnight at 4°C., followed by three washing steps for 
5min with TBS + 0.1% Tween. Next, the membrane was incubated with the secondary 
antibody for one hour at room temperature. The secondary antibody was conjugated to 
horseradish peroxidase (HRP), to visualize the proteins. After incubation with the 
secondary antibody, the membrane was washed again three times for 5min with TBS + 
0.1% Tween. The membrane was incubated for 5min with the detection reagent "ECL 
Plus" (GE Healthcare) according to the manufacturer's instructions. The substrate of the 
working solution and HRP are generating a light emitting precipitate, which binds to the 
antigen-antibody complex. This precipitate was visualized using the "LAS 4000 Imager". 
Blockingsolution: Tris   2,4g 
   NaCl   8g 
   H2O (bidest.)  ad 1l 
   Tween   0,1% 
   BSA   5% 
 
2.2.3 Gene expression analysis 
2.2.3.1 RNA isolation from cells 
The isolation of mRNA from cultured cells was carried out with the spin column- based 
High Pure RNA isolation kit (Roche**) according to the manufacturer’s instructions. 
Briefly, the cells were seeded at a concentration of 1x10
6
 cells per well in 6-well plates and 
stimulated as indicated. Subsequently, cells were washed once with PBS and lysed in 
400μl of the lysis- /binding buffer supplemented with 200μl PBS. While RNases are 
inactivated, the buffer also contains Triton X-100, which mediates the permeabilization of 
the cell membrane as well as guanidine hydrochloride, which induces protein denaturation. 
The samples were vortexed for 15sec to boost cell lysis and subsequently applied onto a 
TBS 
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spin column that consists of glass fiber fleece. Columns were centrifuged at 8000xg for 
15sec, which leads to the binding of the nucleic acids to the column, while proteins, salts 
and cellular debris are eluted. Contaminating DNA was digested directly on the column by 
incubation with DNase I for 15min. The remaining RNA was washed three times, before 
50μl nuclease-free water was added to the column to elute the RNA. Concentration and 
purity were measured with the NanoDrop ND-1000. 
 
2.2.3.2 RNA isolation from tissue 
RNA from tissue was isolated with a modified TRIzol method incorporating a Dnase I 
digestion step. 
For the isolation of total RNA from mice brain, tissue samples were treated with the 
TRIzol (Invitrogen) reagent. First, samples were homogenized, by a motor driven 
micropistille, in 1ml TRIzol in a 1,5ml eppendorf tube, before 200μl chloroform was 
added. This was followed by hand-shaking for 15seconds and incubation at room 
temperature for 5min. Tubes were then centrifuged at 20.000xg for 15min at 4°C which 
results in the formation of three phases with the RNA being present in the colourless upper 
aqueous phase. The upper phase was transferred to a new tube and 500μl isopropanol were 
added. For the precipitation of the RNA, the samples were incubated for 10min at room 
temperature followed by centrifugation at 13.000xg and 4°C for 30min. The pellets were 
washed in 1ml 70% ethanol and centrifuged at 20.000xg and 4°C for 10min. To remove 
DNA, the pellets were resuspended in 50μl DNA digestion mix and incubated for 20min at 
37°C. To purify the RNA, 150μl nuclease-free water and 200μl phenol/chloroform/isoamyl 
alcohol were added. The samples were vortexed for 30sec and subsequently centrifuged for 
2min at 20.000xg and 4°C. The upper aqueous phase, which contains the RNA, was 
transferred to a new tube. 20μl sodium acetate (3M, pH 4,8) and 200μl isopropanol were 
added and samples were incubated for 30min at 4°C to precipitate the RNA before 
centrifugation for 30min at 20.000xg and 4°C. The pellet was washed twice once with 1ml 
70% ethanol and once with 900µl 70% ethanol for 5min each followed by centrifugations 
at 20.000 g and 4°C. Finally pellets were air dried at 37°C for 15min and the RNA was 
resuspended in 20μl to 50μl (depending on the size of the pellet) nuclease-free water. The 
concentration and purity was determined using a NanoDrop ND-1000 spectrophotometer 
(Peqlab). 
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DNA digestion mix: 
5μl DNase I incubation buffer (10x, Roche) 
1μl DNase I (10U/μl, Roche) 
0,5μl RNase OUT (40U/μl, Invitrogen) 
Ad 50μl nuclease-free water 
 
2.2.3.3 Reverse transcription 
In the first step to analyse changes in gene expression by qRT-PCR, the isolated RNA was 
transcribed into complementary DNA (cDNA) by using reagents from the iScript cDNA 
synthesis kit, which includes reverse transcriptase, an RNA-dependent DNA polymerase. 
All mRNA´s were reverse transcribed using random hexamer oligonucleotides or 
oligo(dT) primers, the latter being complementary to the poly-A tail of eukaryotic mRNAs.  
Reaction mix: 
5x iScript reaction mix   4μl  
iScript reverse transcriptase   1μl  
RNA template (1μg)    xµl 
Nuclease-free water   xµl 
 
Total volume    20µl 
 
Standard program:   25°C   5min 
      42°C   30min 
      85°C   5min 
 
Each sample was diluted in a ratio of 1:5 with nuclease-free water and stored at -20°C. 
 
2.2.3.4 Quantitative real-time (qRT-PCR) 
For quantification of gene expression levels and changes in gene expression in tissue or 
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cell lysates qRT-PCR was used. This commonly used method for single gene expression 
consists of two reaction steps. In the first step the RNA is transcribed into cDNA in the 
second step this cDNA is used for amplification by PCR. For detection SYPR- Green was 
used. This fluorescence marker intercalates into dsDNA and therefore, the reaction product 
can be detected as the reaction progresses in real time For the qRT-PCR a thermo cycler 
was used with the capacity to illuminate samples with a beam of light of a specified 
wavelength and to detect such fluorescence. The method follows the general principles of 
the polymerase chain reaction: After activation of a hot-start polymerase, the protocol 
consists of 40 cycles each including three steps: Denaturation of nucleic acids double 
strand, annealing of the primers and DNA polymerization.  
 
10× PCR-Puffer:    Tris-HCl pH 8,8      0,75M  
      Ammoniumsulfat    0,2M  
      Tween-20      0,1% (v/v) 
 
SYBR-Green Master Mix:  10x PCR-Puffer      2,5ml  
      25 mM MgCl2      3ml  
      1:100 SYBR-Green     31,3μl  
      20mM dNTP-Mix     250μl  
      5 U/μl Taq-Polymerase    100μl  
      10% Triton X-100     652μl  
      1M Trehalose     7,5ml 
 
All dilutions were performed with DEPC-H2O and the Trehalose was diluted with Tris-
HCl (pH 8,0).  
 
PCR-Reactionmix:    SYPR-Green Master Mix     5,6 μl  
      fw-Primer (10μM)      0,3μl  
      rv-Primer (10μM)      0,3μl  
      cDNA 5ng/μl      2μl  
      H2O        1,8μl 
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Standard qRT-PCR program: 
   95°C  12min  Activation Taq-Polymerase 
    95°C  15sec  Denaturation   
    60°C  1min  Annealing/Elongation 
    95°C  15sec   
    60-95°C 2°C/min 
 
The reaction mix was placed in a 384-well plate. All qRT-PCRs were performed using the 
HT 7900 Real-Time PCR system. Gene expression was analysed by using the SDS 
software version 2.4 (Applied Biosystems) normalizing the expression to two reliable 
housekeeping genes, murine 18S ribosomal RNA and murine GAPDH. Fold changes or 
∆Ct values were plotted with GraphPad Prism for Windows or Mac (version 6.0e). For 
analysis the comparative cycle threshold (Ct) method was applied as described by Livak 
and Schmittgen, 2001 (Livak and Schmittgen, 2001): 
∆Ct = Ct of gene of interest – Ct of housekeeping gene 
∆∆Ct = ∆Ct of sample - ∆Ct of reference 
Fold change = 2
-∆∆Ct  
 
2.2.3.5 Establishing primers for qRT-PCR reaction 
All used primer pairs were designed with the software PerlPrimer version 1.1.21 (Marshall, 
2004) before they were tested for their efficiencies. The primer pairs were chosen from the 
database BioGPS (Wu et al., 2009). For primer testing, cDNA with a known concentration 
was used. Under optimal conditions each PCR cycle should results in a doubling rate of the 
die, which corresponds to an efficiency of 100% of the respective primer. Only primers 
within a range of 90%-110% efficiency were chosen for experiments. As described before, 
the Ct- values were measured and plotted against the amount of input cDNA. The slope of 
the resulting graph was calculated with SDS software version 2.4; a slope result of -3,33 
40x 
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equals a primer efficiency of 100%. The efficiency can be calculated using the following 
formula:  
10 
-1/slope of the line
 
Furthermore, to verify that a single gene product with the correct size was generated, the 
PCR-products of all used primer pairs were visualized on a 2% agarose gel. 




2.2.4.1 Perfusion, Fixation and Tissue Processing 
Mice were anesthetized with ether before perfusion. Therefore, the skin of the abdomen 
was cut open quickly as well as the pericardium using scissors. A small hole was then cut 
into the right cardiac atrium through which the blood could leave the animal’s body. Then 
10ml phosphate buffered saline (PBS) was thoroughly injected into the left main heart 
chamber thereby pumping the blood out of the circulation system. Total brains were 
dissected out. The anterior part (Fig 6) of the brain (bulbus not included) was snap frozen 
in liquid nitrogen and stored at −80°C until homogenized for gene expression analysis. 
Furthermore, for fixation all tissues were stored for 48hours in 4% Paraformaldehyde (PFA 
at room temperature) at a ratio of fixative to tissue of 10:1. Tissues were stored in PBS 
before further processing. All fixed tissue were processed into a cassette, dehydrated and 
cleared automatically. 
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Fig 6: Schema of a mouse brain and tissue processing. 
The tissue between the red lines was snap frozen, right side (i) as the injected side with the 
injection hole and left side non- injected side (ni) as the control. 
 
Tab 8: Dehydration Protocol 
Time Substance 
3x60min 75% Ethanol 
2x90min 96% Ethanol 
3x75min 100% Ethanol 
2x120min Xylol 
 
Tissue were picked out of the cassette and embedded with pure molten paraffin. For 
microscopic analysis sections of 3µm thickness were cut with a microtome, floated on a 
warm water bath to help remove wrinkles before they were picked up with a glass 
microscopic slide. 
 
Tab 9: Deparaffinization Protocol 
Time Substance 
3x5min Xylol 
2x5min 100% Ethanol 
3min 96% Ethanol 
3min 80% Ethanol 
3min 70% Ethanol 
3min H2O 
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2.2.4.2 Histology staining 
To visualize the morphology haematoxylin and eosin staining, the gold standard was used 
for all samples.  





2min 100% Ethanol 
2min 100% Ethanol 
2min 96% Ethanol 
2min 70% Ethanol 
2min 50% Ethanol 
2min 30% Ethanol 
3min Aqua dest. 
5min Haematoxylin 
10min Tap water 
2min Aqua dest. 
3min 1% Eosin 
1sec Aqua dest. 
1min 70% Ethanol 
1min 80% Ethanol 
1min 90% Ethanol 
1min 96% Ethanol 
2min 100% Ethanol 






Immunohistochemistry (IHC) was performed on all sections of 3μm thickness from 4% 
formalin-fixed, paraffin-embedded tissues.  
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2.2.4.3.1 Cytokeratin 8 (CK8) 
Sections were deparaffinised, unmasked in a steamer for 40min with Citrate buffer (Dako 
Real Target Retrieval Solution 1:10 dilution), washed, and then rinsed with PBS+H2O2 for 
20min before incubation overnight at room temperature with anti- Cytokeratin 8 (dilution 
1:100 Abcam ab 59434). Sections were washed with Tris Buffer and then incubated for 1h 
at room temperature with goat anti rabbit biotinylated antibody (dilution 1:250 Dianova 
111-065-144), washed in Tris buffer, incubated for 1h with Peroxidase (dilution 1:1000, 
Sigma ExtrAvidin – Peroxidase E-2886) and visualized with DAB substrate (DAB 500plus 
Zytomed).  
 
2.2.4.3.2 Ionized calcium binding adaptor molecule (IBA) 
Sections were deparaffinised, unmasked in a steamer for 40min with Citratbuffer (Dako 
Real Target Retrieval Solution 1:10 dilution), washed, and then incubated in PBS+H2O2 
for 20min before incubation overnight at room temperature with Rb Anti Iba-1 (dilution 
1:1000 Wako 019-19741). Sections were washed with Tris Buffer and then incubated at 
room temperature with goat anti rabbit antibodies (dilution 1:250 Biotinylated Dianova 
111-065-144), washed in Tris buffer, incubated for 1h with Peroxidase (dilution 1:1000 
Sigma ExtrAvidin – Peroxidase E-2886) and visualized with DAB substrate (DAB 500plus 
Zytomed).  
 
2.2.4.3.3 Ki67  
Sections were deparaffinised, unmasked in a steamer for 40min with Citrate buffer (Dako 
Real Target Retrieval Solution 1:10 dilution), washed, and then incubated in PBS+H2O2 
for 20min before incubation overnight at room temperature with Anti- Ki-67 antibody 
(dilution 1:200 Abcam ab15580). Sections were washed with Tris Buffer and then 
incubated for 1h at room temperature with goat anti rabbit antibodies (dilution 1:250 
Biotinylated Dianova 111-065-144), washed in Tris buffer, incubated for 1h with 
Peroxidase (dilution 1:1000 Sigma ExtrAvidin – Peroxidase E-2886) and visualized with 
DAB substrate (DAB 500plus Zytomed).  
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2.2.4.3.4 CD34 
Sections were deparaffinised, unmasked in a steamer for 40min with Citratbuffer (Dako 
Real Target Retrieval Solution 1:10 dilution), washing, and the incubated in PBS+H2O2 for 
20min before incubated overnight at room temperature with CD34 rat anti mouse (dilution 
1:500, Klon MEC14.7, Serotec MCA1825GA). Sections were washed with Tris Buffer and 
then incubated at room temperature for 1h with Rabbit Anti-Rat (dilution 1:500 
Biotinylated Dako E0468) washed in Tris buffer, visualized with 3,3’-diaminobenzidine 
(DAB) or either with DAB substrate (DAB 500plus Zytomed).  
 
2.2.4.3.5 Glial fibrillary acidic protein (GFAP) 
Sections were deparaffinised, unmasked in a steamer for 40min with Citratbuffer (Dako 
Real Target Retrieval Solution 1:10 dilution), washing, and the incubated in PBS+H2O2 for 
20min before incubated overnight at room temperature with anti-GFAP antibody (dilution 
1:200, Dako Z0334). Sections were washed with Tris Buffer. Afterwards they were 
incubated at room temperature with Alkaline Phoshatase/red/rabbit/mouse system for 
10min to 15min (Dako Real Detection System K5005).  
 
2.2.4.3.6 Myeloperoxidase (MPO) 
Sections were deparaffinised, unmasked in the microwave for 30min with Tris/EDTA (10x 
Dako S2367 Target Retrieval Solution pH 9), washing, and the incubated in PBS+H2O2 for 
20min before incubated overnight at room temperature with Anti-Myeloperoxidase (MPO) 
antibody (dilution 1:200, Abcam 9535). Sections were washed with Tris Buffer and then 
incubated at room temperature for 1h with goat anti rabbit biotinylated (dilution 1:250 
Dianova 111-065-144), washed in Tris buffer, incubated for 1h with Peroxidase (dilution 
1:1000 Sigma ExtrAvidin – Peroxidase E-2886) and visualized with DAB substrate (DAB 
500plus Zytomed).  
 
2.2.4.3.7 CD3 
Sections were deparaffinised, unmasked in the microwave for 30min with Citratbuffer 
(Dako Real Target Retrieval Solution 1:10 dilution), washing, and the incubated in 
PBS+H2O2 for 20min before incubated overnight at room temperature with Anti-CD3 
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antibody (dilution 1:150, DCS C1597C01). Sections were washed with Tris Buffer and 
then incubated at room temperature for 1h with goat anti rabbit biotinylated (dilution 1:250 
Dianova 111-065-144), washed in Tris buffer, incubated for 1h with Peroxidase (dilution 
1:1000 Sigma ExtrAvidin – Peroxidase E-2886) and visualized with DAB substrate (DAB 
500plus Zytomed).  
2.2.4.3.8 B220  
Sections were deparaffinised, unmasked in the microwave for 30min with Citratbuffer 
(Dako Real Target Retrieval Solution 1:10 dilution), washing, and the incubated in 
PBS+H2O2 for 20min before incubated overnight at room temperature with rat Anti-mouse 
CD45R antibody (dilution 1:200, BD Pharmingen 557390). Sections were washed with 
Tris Buffer and then incubated for 1h at room temperature with goat anti rat biotinylated 
(dilution 1:200 Sigma B7139), washed in Tris buffer, visualized with 3,3’-
diaminobenzidine (DAB) and nuclei counterstained with haematoxylin. 
 
Nuclei were counterstained with haematoxylin for all staining. 
 
2.2.5. Light microscopy 
For the documentation of all preparations the stereomicroscope (Leica Microsystems) was 
used to examined and photographed.  
 
2.2.6 Animal monitoring 
Before injection mice were monitored for their physical fitness. Sensory, or motor deficits 
in the animals that might interfere with their normal behaviour were checked before and 
after surgery. Therefore, all mice were tested for several parameters, including poor 
grooming, changes of the fur, bald patches in the coat, absence of whiskers, laboured 
breathing and body weight loss and abnormalities were recorded. The following tests were 
used to reveal neurological dysfunctions. 
2.2.6.1 Wire Hang Test 
This test is used to evaluate motor function: It investigates neuromuscular strength of 
animals. The mouse is placed on the wire cage lid and the lid is gently waved so that the 
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mouse grips the wire (Fig 7A). The lid is then turned upside down approximately 50cm 
above the surface of the bedding material. 
The latency to fall onto the bedding was recorded. This task was used as a measure of 
grasping ability and an indication for motor function deficiency.  
2.2.6.2 Rotarod Test 
This test is widely used to measure motor coordination and balance and can reveal ataxic 
behaviour. The rotarod measures the ability of the mouse to maintain balance on a rotating 
rod (Fig 7B). Performance is measured as “latency until drop-off”. There are two methods: 
Rotarod: Each mouse is placed on the rotating rod and the time until fall off is measured 
(cut-off time: 60sec). Different constant rotation speeds are used in this paradigm. 
Accelerod: An accelerating rotarod allows the rotation speed to be constantly increased 
from 4 to 40 revolutions per minute (rpm), over a five-minute period. 
Each mouse is placed on the rotarod at a constant speed (12rpm) for a maximum of 120sec 
and the latency and frequency to fall off the rotarod within this time period is recorded. 
 
Fig 7: Behaviour testing systems. 
(A) Wire Hang system and (B) Rotarod system for behaviour testing. 
 
2.2.7 Stereotaxis 
2.2.7.1. Animal use and intracranial cancer cell injection 
Mice, of approximately 20g body weight and eight weeks of age were bred in-house from 
animals purchased from JANVIER SAS and were used for all studies. Female mice were 
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group-housed in Macrolon cages, provided with nesting material without environmental 
enrichment. Mice were provided with water and phytoestrogen-free and soy-free food 
(ssniff Spezialdiäten GmbH), available ad libidum. Cages were held under standard 
conditions within a temperature- and humidity-controlled holding room (22°C; 55-60% 
relative humidity on a 12:12 hour light:dark schedule (lights phase: white light; 
illumination: ~80lx; dark phase: no light)) and housed for four weeks to acclimatise before 
they were used for experiments. Physical examinations were performed before and after 
surgery in an experimental room. Testing was commenced at least one hour after onset of 
the light phase. Thus, potential abnormalities, sensory, or motor deficits, which might 
interfere with data interpretation, would have been detected before the procedure. Mice 
with abnormalities were not used for further studies. 
At an age of 12 weeks, mice were anesthetized with ketamine 100mg/kg intraperitoneal 
(IP) ×1 and Domitor® 0,25mg/kg IP ×1 before injection. Mice were placed into a 
stereotactic frame (Fig 8). This frame employs two devices: a head holder and a 
thumbscrew driven ear-bar advance.  
 
 
Fig 8: Stereotaxis frame. 
Mouse was fixed in the front and also from the left and right side with ear-bar advance (Marchand 
and Riley, 1979). 
 
Different amounts of cells were tested and injected. 3µl (mixture 1:3 cells and extracellular 
matrix (ECM)) were stereotactically injected through a 0.5- 1mm burr hole by using a 
Hamilton 10µl syringe. Brain coordinates relative to bregma (Franklin KBJ, Paxinos G.; 
The Mouse Brain in Stereotaxic Coordinates. San Diego: Academic Press; 1997. 
10.1111/j.1469-7580.2004.00264.x.), were posterior -2.0, lateral 1.0, ventral -3.5 and 
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dorsal +0.5 to the right hemisphere. The opening of the needle pointed to the left. The 
syringes remained in place for a period of 3min to minimize reflux through the needle 
track. Afterwards, the needle was removed under simultaneous rinsing with physiological 
saline solution from the brain. The burr hole was then closed with bone wax and the scalp 
stitched.  
Mice were weighed and checked on biweekly basis at minimum to monitor metastasis 
development. 
 
2.2.7.2 Cancer cell preparation for injection 
In case of adherent cells, cells were observed before for they had reached 70-80% 
confluency. Cells were washed with PBS and detached by incubation with 1ml Trypsin 
(1:5) for up to 15min. Cells were calculated in Neubauerzählkammer.  
 
2.2.7.3 Application of LGK974 
For application of LGK974 gavage (stomach tube) was used. LGK974 was diluted in 
sterile H2O 50µl to 60µl depending on the body weight were applied with a concentration 
of 3mg/kg body weight.  
 
2.2.8 Chorioallantoic Membrane (CAM) Assay 
This method is widely used as a method to study angiogenesis, cancer cell invasion and 
metastasis. Murphy (1912) used the fertilized chicken egg membrane as a respiratory organ 
and studied tumour invasion using this method. The advantage of this model are a highly 
nature vascularisation which can promote tumour cell growth, it is very reproducible and 
comparable to animal models with less but at lower costs. Furthermore, the CAM itself 
contains ECM and therefore mimics the physiological cancer cell environment.  
Here, cancer cells are placed on the developing embryo of a chicken egg at the tenth day 
after fertilisation. Alternatively cancer cells that have been treated with the substance to be 
tested can be used. The embryos are incubated for a desired time before the effects of the 
substance or tumour growth can be analysed. Specific pathogen free eggs were used, which 
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were purchased from Charles River (Sulzfeld). Eggs were incubated at 37°C and at a 
relative air humidity of 80%. To amenable access of the tumour cells to the CAM, eggs 
were windowed on the third day of incubation. Therefore eggs were sawed in the bubble, 
so that the air can escape from the egg and the embryo can descend and separate from the 
shell. Furthermore, a small opening was sawed into the shell above the embryo. Before the 
eggshell was lifted, a Locke's solution was used to separate the shell from the membrane. 
Next, the opening was covered with Leukosilk S (BSNmedicalGMBH, Hamburg) and eggs 
were incubated for another seven days. In the next step, different cancer cells or cancer 
cells plus inhibitor were placed on the CAM. In case of 410.4, 3×10
6
 cells in 40µl ECM (R 
& D Systems, Wiesbaden-north city) were resuspended and then placed directly on the 
CAM. Additional 1x10
5
 of 4T1 cell and 1x10
5
 E0771LG cell were resuspended in 40µl 
ECM and placed on the CAM. After covering with Leukosilk S, eggs were incubated for 
another seven days. For fixation CAM and tumour tissue was removed from the eggs and 
incubated overnight in 4%PFA. Afterwards the tissue was washed in stored in PBS before 
tissue Processing as described. 
 
Locke's solution:   NaCl (1,61M)   100ml 
     KCl (0,16M)   37ml 
     CaCl2 (0,14M)  21ml 
 
 
Fig 9: Preparation of CAM. 
(A) Opened Egg with tumour. (B) Membrane with tumour 
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2.2.9 Software analyses 
Aperio ImageScope viewing software from Leica practical on digital slide images, which 
can adjust enlargement and can compare different stains, interpret areas of interest, and 
perform image analysis. Analysis provides automated quantification for the exact 
evaluation of staining patterns. Therefore, slides were digitised on a scanner and volume of 
the tumours were measured and evaluated. 
 
2.2.10 Statistics  
GraphPad PRISMA® Version 6.0e software was used for the calculation of significance 
with the two-sided unpaired t-test. Results with a p-value <0.05 were considered 
significant. GraphPad PRISMA® Version 6.0e software was also used for the Kaplan 
Meier survival curves. All experiments were performed at least in biological triplicates. All 
data are displayed as means±SD (standard deviation). 
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3 Results 
3.1. Characterisation of cancer cell lines 
One of the major aims of this thesis was to establish a syngeneic mouse model to 
investigate the colonization of cancer cells in the central nervous system. Therefore, we 
first had to identify suitable breast cancer cell lines from mice, test their biological features 
and characterize their gene expression profile. 
One of the potential cell lines we came up with is the breast cancer cell line 410.4. This 
mamma- adenocarcinoma cell line was originally isolated from a single spontaneously 
arising mammary tumour from a BalbC mouse (Miller, 1983). The subclone 4T1 was 
derived from 410.4 after treatment with thioguanine, which resulted in a thioguanine-
resistent 4T1 cell line (Aslakson and Miller, 1992b). The 4T1 cancer cell line is able to 
metastasise spontaneously in the lungs and liver and appears to enter the blood stream 
without involvement of the lymph nodes while the metastatic potential of 410.4 has not 
been investigated yet. The third breast cancer cell line used in this study is the 
adenocarcinoma cell line E0771. EO771 was originally isolated from a spontaneous cancer 
of a C57BL/6 mouse. The E0771LG we used was provided by Jeffrey Pollard. This is a 
more aggressive subclone of the EO771. In the laboratory of Jeffrey Pollard, E0771 cells 
were injected intravenously into C57BL/6 mice, and the cells isolated from lung metastatic 
foci were cultured to obtain the highly metastatic subclone EO771LG (Ewens et al., 2005).  
 
3.1.1 Cell lines morphology  
First, to identify differences in cancer cell morphology, cancer cell lines 410.4, 4T1, 
E0771, and E0771LG were cultivated for 48hours until they had reached a confluency of 
70%. For documentation, pictures were taken with an inverted microscope. The cancer cell 
lines 410.4 and 4T1 grew with a comparable morphology and typical epithelial 
characteristics (Fig 10). The E0771 and E0771LG showed no differences, however, in 
contrast to 410.4 and 4T1, they revealed obvious mesenchymal morphology (Fig 10).  
  




Cell line Morphology 
410.4 
The cells grow as a monolayer 
with epithelial morphology. 
Cells are polygonal in shape 
with more regular dimensions, 
and grow in patches/groups. 
 
4T1 
Cells grow similar to 410.4. 
4T1 cells grow as single cells 
before they grow in patches.  
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Fig 10: The morphology of the four breast cancer cell lines used in this study. 
The morphologies of the cancer cell lines 410.4, 4T1, E0771 and E0771LG are shown. 
 
3.1.2 Gene expression for the characterisation of cancer cell lines 
The morphology of the E0771 and E0771LG cell lines indicates a more mesenchymal 
phenotype as compared to the other lines implicating differences in the epithelial and 
mesenchymal characters of these cell lines (3.1.1). In order to examine this implication, 
further and to prove the impact of EMT and MET in metastasis, cancer cell lines were 
characterised for their gene expression patterns using Real-Time-quantitative-PCR. 
Typical markers were used for epithelial (Ecad) (Fig 11A) and for mesenchymal 
characterisation (Vimentin) (Fig 11B). 
Cell line Morphology 
E0771 
The cells grow as a monolayer. 
Fibroblast-like cells are bipolar 




Cells grow similar to E0771 
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Fig 11: The expression level of E-cadherin (A) and Vimentin (B) revealed differences in the 
epithelial or mesenchymal character of the different breast cancer cell lines. 
The expression of E-cadherin (Ecad) and Vimentin was assessed by qRT-PCR from total RNA 
samples of the cancer cell lines 410.4, 4T1, E0771LG and E0771 (GOI = gene of interest, HK = 
housekeeper). Error bars show SD, values, statistics sign was tested using unpaired, two tailed 
students t-test. (A) Both, the 410.4 and the 4T1 showed high expression levels of Ecad compare to 
the both EO771 cell lines. (B) The 410.4 showed low expressions levels of Vimentin compare to 
all other cell lines. Interestingly, the 4T1 demonstrated significantly higher expression of Vimentin 
compared to 410.4 (p= <0.0001). 
 
Ecad as a marker for epithelial cells was highly expressed in the cancer cell lines 410.4 and 
4T1, which underlined the epithelial character of these cell lines. The expression level in 
all other cell lines was lower compared to 410.4 and 4T1 and therefore an indicator for a 
mesenchymal character. Vimentin, an intermediate filament protein, which is expressed in 
mesenchymal cells, is often used as a marker for cells undergoing EMT during normal 
development as well as during metastatic progression (Thiery, 2002). In our tests lowest 
significant expression of Vimentin was measured in the 410.4 cell line, and high 
expression was detected in 4T1, E0771LG and E0771. With respect to 410.4 it would be of 
interest, if these cell types differ in their colonization capacity in the planned in vivo 
experiments.  
To be able to demonstrate the presence of cancer cells in tissue samples obtained from 
mice later, after the injection of these carcinoma cells into the brain, we screened them for 
typical markers. Breast cancer cells often express increased levels of Cytokeratin 8 (CK8). 
Indeed, CK8 was highly expressed in all four cell lines and could therefore be used as a 
potent marker to measure the content of breast cancer cells in the brain tissue, which 
normally expresses low amounts of CK8 (Fig.12). 
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Fig 12: Gene expression of CK 8 in different cancer cell lines. 
The expression of CK8 was assessed by qRT-PCR from total RNA samples of the cancer cell lines 
410.4, 4T1, E0771LG and E0771 (GOI = gene of interest, HK = housekeeper), qRT-PCR for 
Cytokeratin 8 in murine mamma carcinoma cell line 410.4, 4T1, E0771LG and E0771. Statistics 
sign was tested using unpaired, two tailed students t-test Interestingly, there were no significant 
differences between the four breast cancer cells. 
 
After establishing CK8 as a suitable marker to identify tumour masses that may develop 
from the injection of breast cancer cell lines we plan to use in this study, we can now focus 
on the next step: establishing syngeneic in vivo models, which I will describe in the next 
section. 
 
3.2. Establishing of a syngeneic mouse model 
3.2.1 Investigation of cerebral metastasis development 
Cerebral metastasis is a severe clinical implication with mostly fatal outcomes for the 
patients. Almost 30% of metastasized breast cancer patients suffer from brain metastases 
and this incidence is increasing. However, animal models for brain metastases are limited. 
Furthermore, the immune cells and immune signalling play an important role during the 
colonization of the brain (Lorger and Felding-Habermann, 2010). In order to investigate 
the role of the resident innate immune cells, the microglia, during cerebral metastasis, the 
establishment of syngeneic mouse models is needed. Also, to test immune based 
therapeutic strategies in vivo as well as for a better understanding of the role of blood-
derived immune cells during the colonization of the brain, immune-competent mouse 
models are required. However, until now the majority of the investigations on metastatic 
diseases are performed using a Xenograft model, that is in immunocompromised mice 
(Morton and Houghton, 2007). 
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In order to establish syngeneic cerebral metastasis mouse models, different amounts of 
410.4, 4T1, E0771LG, and E0771 cancer cells were intracranially injected in immune-
competent BalbC or C57BL/6 female mice, respectively. After the procedure, all mice 
were observed carefully and behaviour tests (Hanging wire and Rotarod tests) as well as 
weight measurements were performed to screen and follow–up the injected mice (data not 
shown and Fig 7). Mice displaying abnormal neuronal deficiencies as revealed by the 
inability to successfully complete the Hanging wire or Rotarod tests, or losing weight 
(>20%), were dissected immediately. The inability to complete these tests was documented 
through movies and photos. After sacrificing, potential tumour mice, the brain tissues were 
dissected and macroscopically photographed to document the tumour growth (Fig 13). 
Furthermore, every mouse was catalogued by age, injection date and dissection date and 
based on this data survival curves for experimental groups were generated (Fig 14).  
 
Fig 13: Preparation of mouse brains after the colonization of different cancer cell lines. 
BalbC mice were injected with 410.4 and 4T1 cancer cells and compared with the control (CTL 
=injected only with ECM/medium without breast cancer cells). C57BL/6 mouse were injected with 
E0771LG. Injection whole was labelled with “x”. 
 
BalbC mice were injected with different amounts of 410.4, 4T1 and E0771LG embedded 
in ECM, and ECM alone as controls (CTL). 
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Fig 14: Kaplan Meier survival curves of mice.  
(A-C) Survival days of mice after injection of different amounts of cancer cell lines 410.4, 4T1 or 




(n=8) injected 410.4 
cells. (B) Control (n=5) vs. 1x10
3




(n=3) injected 4T1 cells. (C) 




 injected E0771LG cells.  
 
In case of 1x10
4
 injected 410.4 cancer cells, only one out of four mice developed cerebral 
metastasis (n=4) while all mice developed metastasis after the injection of 2,5x10
4
 410.4 
cancer cells.  Interestingly, this finding indicated that there is a threshold regarding the 









 cells (data not shown) of 
cancer cell line 4T1 embedded in ECM were injected in BalbC mice (Fig 14B). All 
injected mice with the 4T1 cancer cell line developed metastasis independently of the 
amount of injected cells. Furthermore, the amount of cells seemed also not to influence the 
overall survival of the mice. All mice died in the same range between day seven and 22. 
Therefore, we underlined the assumption that the subclone of the 410.4, 4T1 has a 
significant better ability to colonize the brain tissue. Here, injecting 1x10
3
 4T1 cancer cells 
is enough for cerebral metastasis development and can be used for further experiments.  
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To test the colonisation capacity of the EO771LG breast cancer cell line C57BL/6 mice 




 cells (data not 
shown), 2,5x10
4
 cells (data not shown) and 7,5x10
4
 cells embedded in ECM (Fig 14C). 
Additionally, as a control (CTL), C57BL/6 mice were injected with ECM alone. All mice 
developed metastasis within 21 days. For this reason we decided to perform further 
experiments with 500 cells.  
Interestingly, the mean overall survival (OS) of mice injected with the cancer cell line 
410.4 was 50 days (Fig 14A), in comparison to the mean OS of 21days following injection 
with cancer cell line 4T1 (Fig 14B). C57BL/6 mice injected with lower amounts of the 
cancer cell line E0771LG survived 15days (Fig 14C). During and after dissection, brain 
tissues were macroscopically observed. We observed frequent bleedings in the E0771LG 
model in contrast to the 410.4 and 4T1 models (Fig 13). Even after the very short OS of 
the EO771LG injected mice, we could detect massive tumour cell colonization. In contrast 
to the 410.4 and 4T1, mice injected with the cancer cell line E0771LG died immediately 
after the first observation of behavioural symptoms. All injected BalbC mice - independent 
of the cancer cell line - showed first symptoms without the necessity to sacrifice the mice 
immediately. These first symptoms include motor function abnormalities e.g. 
hyperactivities or ambulation with at least one full 360° turn. There was a period of up to 
one week between observation of first symptoms and the failure of the described 
behaviour. 
In summary, four syngeneic cerebral metastasis mouse models were established by 
stereotactic injection of four different breast cancer cell lines. Additionally, the amount of 
cancer cells for metastasis development was experimentally determined and was used for 
the following studies. Significant differences in OS and the amount of cells for successful 
metastasis were detectable between 410.4 and 4T1. However, there were no differences 
between the cancer cell lines E0771LG and E0771. Moreover, different colonization 
patterns of the cancer cell lines were investigated. 
 
3.2.2 Histological investigation of colonized breast cancer cells metastasis 
To confirm the macroscopic results and to analyze the induced tumours in greater detail, 
histology, IHC and qRT-PCR from the brain tissue samples were performed. Therefore, 
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tissue sections of each mouse were stained using the gold standard HE, to see whether they 
show the presence of colonized breast cancer cells in the brain.  
 
Fig 15: Cell lines derived from BalbC/C57BL/6 mice have metastatic potentials. 




cells) and E0771LG (500cells) were tested 
for metastatic potentials in BalbC or in case of E0771LG in C57BL/6 mice. HE stained sections 
show the presence of colonized cancer cells in the brain.  
 
All HE stained sections displayed the presence of metastasis in the brain. Here, the 
differences of cancer cell lines on metastasis development are conspicuous (Fig.15). 
Most importantly, in contrast to previous reports we detected that the colonized cells not 
only form a macroscopic metastasis but also that colonizing cells detach from the 
metastatic mass and infiltrate into the adjacent brain tissue. This is in contrast to the 
current view that cerebral metastasis growth only displacing with a glial pseudo-capsule 
and without infiltration. This unexpected finding raised several questions, in particular, 
what is the biological consequence of these cells infiltrating brain parenchyma. 
Additionally, we detected carcinoma cells at the meningeal and in distinct samples also in 
the ventricles. These findings indicated that the cells are potential sources for further 
dissemination in the affected brains. In some experiments we detected contralateral to the 
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injection site also colonized metastatic cells confirming this hypothesis. Thus taken these 
findings together, it seems that metastasis have the potential to disseminate and metastasize 
again, at least in the brain. 
Moreover, the infiltration pattern into the adjacent brain parenchyma varied between the 
syngeneic models. While the 410.4 injected cancer cells showed cohort infiltration patterns 
(Fig 15). 4T1 cancer cells showed the same cohort infiltration pattern, however, with a 
significantly higher extent. In contrast, the E0771LG cancer cell line demonstrated single 
cell, diffuse infiltration into the adjacent brain parenchyma. To demonstrate the presence 
of colonized cancer cells in the brain and confirm previews findings, we used the marker 
CK8 (Fig 16). Therefore, CK8 staining was performed in one of each sectioned, injected 
mouse brain with 410.4, 4T1 and E0771LG cancer cells.  
 
Fig 16: Quantification of cancer cell lines and metastatic potentials. 




cells) and E0771LG (500cells) were 
tested for CK8. CK8 staining was performed for sections with injected cancer cell lines 410.4, 4T1 
and E0771LG. CK8 staining show clearly the presence of colonized tumour cells in the brain.  
 
Here, it was possible to verify the gene expression results. These findings correlate well 
with the results of cancer cell gene expression obtained by qRT-PCR (Fig 12). CK8 was 
3 Results 56 
 
highly expressed in the metastasis of the cancer cells 410.4 and 4T1. Expression of CK8 in 
E0771LG could also be detected, however with lower intensity. This important observation 
might be useful for the quantification of metastasis development in the brain. The slightly 
lower expression of CK8 in E0771LG could be explained by the fact that Cytokeratin 
expression in primary human mammary carcinomas correlates with clinicopathologic 
variables (Willipinski-Stapelfeldt et al., 2005). CK19 was highly expressed in E0771LG, 
however, CK19 showed low expression in the other cancer cell lines (data not shown). 
Therefore, CK8 was routinely used as a standard in further experiments. 
Fig 17: Representative examples for different infiltration patterns of cancer cell lines. 
CK8 stained sections reveal different infiltration patterns. (A) Infiltration of cancer cells over the 
hemisphere gab in the brain, (B) colonization decay of meningeal and (C) colonization decay of 
ventricle. 
 
After staining, the metastatic potential was investigated and histological sections were 
compared with the corresponding cell lines. In case of 410.4 injected cancer cells, 
metastasis were growing particularly over the gap to the other hemisphere (Fig 17A). 
Vascularisation of the metastasis was detectable. Metastasis enlarge as a cohort and 
therefore similar to the cell line-growth pattern. Also, lots of necrosis leads to lesions in the 
tissue. A metastasis growth pattern similar to that of 410.4 was observed after injecting of 
4T1 cancer cells (Fig 15). These metastases enlarge as cohort, with a more aggressive 
behaviour. They perform more vascularisations and grow rapidly through the brain over 
the hemisphere gap. A representative example was shown in Figure 17A. Metastasis 
resulting from the injection of E0771LG cells grows differently: Single colonized tumour 
cells or small groups of colonized tumour cells were detectable and vascularisation was 
performed. Colonized tumour cells attacked meningeal. An example for attacked 
meningeal was shown in Figure 17B. A representative example for attacked vessels and 
ventricles were shown in Figure 17C and were spread within the brain. Also, here the 
colonized tumour cells grow similar to the cell line. The differences in infiltration patterns 
are listed in Tab 11.  
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410.4 4T1 E0771LG 
Single-cell-
infiltration 
yes yes yes 
Cohort 
colonization 




  yes 
Colonization 
decay of Vessels 
yes yes yes 




  yes 
 
In our group it was recently demonstrated that microglia are critical for the invasion of 
cancer cells into the brain. Moreover, Giulian already confirmed (1993) this finding and 
also that the brain responds to brain injuries with a glial reaction. Microglia and astrocytes 
are found next to the injured site where they build a “glial-wall”. To confirm these findings 
in our syngeneic models one section of each mouse brain was stained with a marker for 
astrocytes (GFAP), (Fig 18) and macrophages/microglia (IBA), (Fig 19). Additionally, in 
terms of an immune reaction CD3 and MPO were stained on consecutive brain sections. 
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Fig 18: Identification of immune reaction after injection of cancer cell lines (GFAP). 




cells) and E0771LG (500cells) were 
immunologically tested for astrocytes activation with GFAP. GFAP staining was performed for all 
sections. All staining showed clearly the presence of astrocytes activation in the brain. 
 
GFAP was detected in all slices, which indicates the presence of activated astrocytes. 
Interestingly, there were differences in the localisation of the astrocytes. In the sections of 
the injected brain with cancer cell line 410.4, the metastasis was clearly separated from the 
astrocytes; they were able to build a wall around the metastasis. In case of injected brains 
with 4T1 cancer cells, astrocytes were also found partly in the metastasis, however 
astrocytes were able to build a wall around the metastasis and the infiltration was similar to 
the infiltration of 410.4 cancer cells. Indeed, in cancer cell lines E0771LG, astrocytes were 
found in the metastasis and around. No wall was built by the astrocytes here. Nevertheless, 
in all cases activation of astrocytes was found around the metastasis but much less in the 
non-injected healthy side. In a next step, the microglia activation was investigated on 
sections stained with the macrophages/microglia marker IBA. 




Fig 19: Identification of immune reaction after injection of cancer cell lines (IBA). 




cells) and E0771LG (500cells) were 
immunologigally tested with the macrophages/microglia marker IBA. Staining was performed for 
all sections. All staining showed clearly the presence of microglia activation in the brain. 
 
All sections showed the presence of activated microglia cells/ macrophages (Fig 19). In 
contrast to the activation patterns of astrocytes, microglia cells were present around and 
between the colonized tumour cells. Furthermore, activated microglia were present in the 
brain, also in the healthy non-injected side. Microglia cells were found mostly close to 
vessels or colonized breast cancer cells.  
This leads us to suggest, that the immune response to colonized cancer cells is very 
diverse. First, injection of different cancer cells showed different localisation patterns of 
activated astrocytes and microglia. In particular, the localisation of astrocytes was 
different. Astrocytes were able to build a wall in case of metastasis developed from 410.4 
and 4T1 but not in metastasis developed from E0771LG. Second, microglia cells are 
located differentially: No wall was built by microglia comparable to that of astrocytes. 
This interesting finding will give the possibility to investigate the role of the glial response 
in different metastasis in more detail.  
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Furthermore, immunostaining with other markers such as Ki67 was performed (data not 
shown). Ki67 is a common marker for proliferation and is often correlated with clinical 
courses of cancer. Here, in all sections Ki67 was expressed (data not shown). In order to 
investigate differences in the proliferation of metastatic cells, Ki67 needs to be further 
quantified in the near future. Next, staining with CD34 (data not shown), which is 
established as a marker of microvascular structures in breast cancer (da Silva et al., 2009), 
was performed to investigate differences between metastasis. Further analyses need to be 
done to detect differences in the vascularisation induced by various cancer cells. In the 
near future, we plan to analyse these histological sections with the software “Definiens 
Tissue Studio”, which allows us to quantify the expression levels in great detail and to 
reveal potential variance.  
These results present previously unknown differences in colonization capacity, infiltration 
pattern into the adjacent brain parenchyma as well as in the glial reaction against breast 
cancer cells of various origins.  
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3.2.3 Gene expression in the metastasis and corresponding cancer cell lines 
In the first part of this thesis, various gene expression markers were established and 
investigated in the cancer cell lines by qRT-PCR. The first two markers, Ecad and 
Vimentin were used to investigate the epithelial and mesenchymal character. In order to 
investigate these characteristics after injection of the cancer cell lines into the brain, these 
genes were analysed in the parts of the brain tissues containing metastases (Fig 20). 
 
Fig 20: Gene expression of E-cadherin and Vimentin in cancer cells and metastasis. 
The expression of Ecad and Vimentin was assessed by qRT-PCR from total RNA samples of the 
cancer cell lines 410.4, 4T1 and E0771LG, also RNA samples from control brain and developed 
metastases of the cell lines (GOI = gene of interest, HK = housekeeper). Error bars show SD, 
values, statistics sign was tested using unpaired, two tailed students t-test. (A) Ecad is highly 
expressed in the cancer cell line 410.4 and 4T1. E0771LG show lower expression of Ecad. Injected 
brains with ECM were used for control (CTL), metastases (=met) developed from 410.4, 4T1 and 
E0771LG show high level on Ecad expression, the highest significant expression was demonstrated 
in metastasis developed from 410.4 compare to the control (B) Vimentin was highly expressed in 
cancer cell lines 4T1 and E0771LG and lower expression level in cancer cell line 410.4. Vimentin 
was expressed in the control, significantly higher expression in metastases developed from 410.4 
and 4T1. Vimentin was expressed in metastasis developed from E0771LG. 
 
When comparing the cell lines by using 410.4 as a reference, Ecad was significantly 
decreased in the cancer cell line E0771LG (p=<0.0001) (Fig 20A). Metastatic samples of 
410.4 expressed significantly more Ecad compare to the control tissue (p=0.0041) (Fig 
20A). Metastasis and corresponding cancer cell line 410.4 demonstrated significant higher 
expression levels of Ecad. However, there are no significant changes between metastatic 
tissue and the cell line. Interestingly, the cancer cell line E0771LG showed low expression 
levels of Ecad, while the metastasis expressed higher levels of Ecad. In a next step gene 
expression-studies of Vimentin were performed (Fig 20B). Metastatic samples of 410.4 
expressed significantly higher expression of Vimentin compared to the control tissue 
(p=0.0264) (Fig 20). When comparing the cell lines by using 410.4 as a reference, 
Vimentin was significantly increased in cell lines 4T1 (p=0.0009) and E0771LG (p=0.01) 
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(Fig 20B), and the corresponding metastasis also showed high expression levels of 
Vimentin, which were clearly higher than the control in all syngeneic models. Vimentin 
expression in metastatic samples of 4T1 was significantly higher (p=0.0246) (Fig 20B) as 
in control samples.  
The next gene expression analysis was to confirm Cytokeratin 8 as a quantification marker 
for tumours developed from the injection of cancer cell lines.  
 
Fig 21: Gene expression of Cytokeratin 8 for quantification in cancer cells and corresponding 
cerebral metastatic tissue. 
The expression of CK8 was assessed by qRT-PCR from total RNA samples of the cancer cell lines 
410.4, 4T1 and E0771LG, also RNA samples from control brain and developed metastases of the 
cell lines (GOI = gene of interest, HK = housekeeper). Error bars show SD, values, statistics sign 
was tested using unpaired, two tailed students t-test. CK8 is expressed in all cancer cell lines. 
Injected brains with ECM were used for control (CTL) shown low expression on CK8. Metastases 
(=met) of 410.4, met of 4T1 and met of E0771LG show high levels CK8 expression.  
 
Here, CK8 expression in the cancer cell lines was confirmed (Fig 21A) and metastasis of 
the cell lines 410.4, 4T1 and E0771LG show significant higher expression levels of CK8 
compared to the control. When comparing the cell lines by using 410.4 as a reference, CK8 
was significantly decreased in the cancer cell line 4T1 (p=0.0395) (Fig 21). In all 
metastatic samples, CK8 expression was significantly higher in comparison to the control 
sample (p=<0.0001) (Fig 21). Thus, expression of CK8 detected by qRT-PCR confirmed 
the findings of metastatic cells in the brain tissue and can be used for quantification. The 
results clearly showed that after injection of cancer cell lines, the corresponding 
developing metastasis can express characteristic genes – such as CK8- which can be used 
for quantification and are reproducible in subsequent experiments.  
All these results underline that a syngeneic cerebral metastasis mouse model for the study 
of cancer metastasis has been established here. This model is applicable for different 
cancer cell lines displaying different characteristics with respect to their epithelial and 
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mesenchymal character and therefore metastatic potential. All cell lines were able to 
colonize the brain and to develop cerebral metastasis. Colonized cancer cells can be 
quantified with CK8. Importantly, all developed metastasis present different colonization 
patterns, which might be related to differences in their phenotype as well as differences in 
their gene expression, we investigate the epithelial and mesenchymal character of 
colonized cancer cell.  
 
3.3. Application of a syngeneic cerebral metastasis mouse model 
In the next part of the thesis we aimed to use the new established syngeneic cerebral 
colonization models of breast cancer to study the impacts on innovative therapeutics. 
Current treatments are of limited efficiency in the treatment of CNS metastasis because of 
several reasons. One is that so far very little is known about how breast cancer cells and 
others colonize this well protected organ and which signalling cascades orchestrate this 
process. Previously, others and we have demonstrated that the dysregulation of Wnt 
signalling is associated with cerebral metastasis in breast cancer (Chuang et al., 2013) 
(Klemm et al., 2011) (Smid et al., 2008) (Pukrop et al., 2010b). In general, the Wnt 
pathway is known to play a role in various processes in cancer initiation, proliferation and 
the first steps of metastasis, thus inhibitors of the Wnt pathway may be valuable for a 
therapeutic strategy also during colonization of the CNS. Therefore we studied a Wnt 
inhibitor in our established syngeneic cerebral metastasis mouse models (4T1 and 
EO771LG) that has already entered clinical trials.  
 
3.3.1 Wnt expression levels of cancer cells  
In order to confirm that the Wnt inhibitor LGK974 has an impact on Porcupine and 
therefore on Wnt secretion, cancer cell lines 410.4, 4T1 and E0771LG were tested for gene 
expression levels of Wnt molecules. Additionally, Porcupine expression levels were 
analysed in these cancer cell lines. Identification of markers, which are specifically 
expressed in cancer cells, could prove the inhibitory effect of LGK974 on Porcupine in 
later experiments.  




Fig 22: Gene and Protein expression level of cancer cells. 
(A) Gene expression level of Wnt5a, Wnt5b, Wnt7a, Wnt6, Wnt10a and Porcupine in cancer cell 
lines 410.4 (n=3), 4T1 (n=3) and E0771LG (n=3) (GOI = gene of interest, HK = housekeeper). 
Error bars show SD, values, statistics sign was tested using unpaired, two tailed students t-test. 
Wnt5a, Wnt5b, Wnt6 was highly expressed in cancer cell line E0771LG. Wnt7a was highly 
expressed in cancer cell lines 410.4 and 4T1. Wnt10 was expressed in cancer cell line 410.4. 
Porcupine was expressed in all tested cancer cell lines. (B) Protein expression levels of Wnt7a/b 
and Wnt5a in cancer cell lines 410.4, 4T1 and E0771LG. 410.4 and 4T1 show high expression of 
Wnt7a/b, Wnt5a was expressed in E0771LG. 
 
Wnt genes and Wnt pathway components were screened, by using the NanoString 
technology (http://www.nanostring.com) (data not shown). Out of the 105 tested genes in 
the cancer cell line E0771LG Wnt5a, Wnt5b and were highly expressed and therefore 
selected for further investigations. In order to investigate expression levels of Wnt5a, 
Wnt5b, Wnt7a, Wnt6, Wnt10a and Porcupine qRT-PCR were performed (Fig 22A). Wnt5a 
was significantly higher expressed in the cancer cell line E0771LG compared to the cancer 
cell lines 410.4 (p=0.0003) and 4T1 (p=0.0009) (Fig 22A). In contrast, Wnt7a was highly 
expressed in both 410.4 (p=0.0024) and 4T1 (p=0.0139) cancer cell lines (Fig 22A) 
compared to the cancer cell line E0771LG. This significant difference was confirmed on 
the protein level (Fig 22B). Furthermore, the potential therapeutic target Porcupine was 
3 Results 65 
 
expressed in all tested cancer cell lines. These results provide the basis for targeting Wnt 
signalling in the above described established syngeneic cerebral metastasis models of these 
cell lines by inhibition of Porcupine.  
 
3.3.2 Investigation of treatment application  
In order to investigate the effect of the Porcupine inhibitor LGK974 on cellular viability, 
MTT measurements were performed with various cancer cells and different LGK974 
concentrations (Fig 23A): Additionally, some concentrations of LGK974 were tested in 
xCelligence measurements (Fig 23B). Here, cells were stimulated for 24hours before the 
xCelligence measurements (pre-treatment). Based on these testing’s we used 2,5µM and 
5µM LGK974 in further functional tests.  
 
Fig 23: Viability of cancer cells after treatment with different doses of LGK974. 
(A) MTT assay LGK974 treated for 96h of 410.4 (n=3), 4T1 (n=3) and E0771LG (n=3). Tested 
dose of LGK974 between 1µM and 100µM (0µM for control) and (B) 2,5µM and 5µM for all cell 
lines, xCelligence measurements of 410.4 (n=3), 4T1 (n=3) and E0771LG (n=3) pre-treated for 24h 
and treated for 48h with LGK974.  
 
The MTT results of the proliferation assay (data not shown) demonstrated, that an 
inhibitory effect of LGK974 was increased, when cancer cells were pre-stimulated with 
LGK974, without a toxic effect on these cells. Based on viability (Fig 23A) and 
proliferation tests (Fig 23B), an effective dose of 5µM of LGK974 for further experiments 
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was investigated. Moreover, a pre-treatment for 24hours with an LGK974 dose of 5µM 
was determined to be optimal.  
Next, to confirm the effects of Porcupine inhibition on the Wnt-release of the LGK974 
treated cells, cancer cells were treated with 2,5µM, 5µM and 10µM of the Porcupine 
inhibitor for 24h. Untreated cancer cell lines served as controls. A concentration of 5µM 
was used to test the time dependent effect of the Porcupine inhibitor LGK974 and cancer 
cells were stimulated for 0, 4, 12, 24 and 48hours. The control was the untreated cancer 
cell line at the corresponding time. To investigate the inhibitory effect of LGK974 on Wnt 
secretion, expression levels of Wnt7a/b and Wnt5a were analysed in the whole cell lysates 
of the treated cells.  
 
Fig 24: Effect of LGK974 on protein expression of Wnt7a/b and Wnt5a in cancer cells. 
(A) Westernblot: Comparison Wnt7a/b or Wnt5a expression with different concentration of 
LGK974 on cancer cells lines to the additional untreated control cell line (CTL). (B) Comparison 
of Wnt7a/b or Wnt5a expression with a concentration of 5µM LGK974 of different time points on 
cancer cell lines. 
 
Wnt5a expression was clearly decreased in E0771LG after LGK974 treatment; however, 
interestingly, the inhibitory effect of LGK974 on protein level seemed to cause an 
enrichment of the protein in 410.4 and 4T1 cancer cell (Fig 24A). These results were 
confirmed with the time dependent treatment strategy, when cancer cells were pre-
stimulated 24hours with 5µM LGK974 and afterwards also stimulated with the same 
concentration of LGK974. After 24hours and 48hours we detected the strongest effect of 
LGK974. Wnt7a/b was enriched in the cancer cells 410.4 and 4T1 treated with LGK974. 
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Thus, the effect of LGK974 was clearly shown, and the Porcupine inhibitor influenced 
Wnt secretion as expected.  
 
Afterwards, we investigated the invasion capacity of various breast cancer cells after 
treatment with these two LGK974 concentrations and the stimulation for 24hours before. 
The results are demonstrated in Figure 25. 
 
Fig 25: Invasion of cancer cells after treatment with different doses of LGK974. 
Invasion assay of 410.4 were performed with microglia (MG) (n=3) to increase invasion of cell line 
410.4 and pre-treated 24h and treated 48h with 2,5µM and 5µM LGK974, 4T1 (n=3) and E0771LG 
(n=3) were pre-treated 24h and treated 48h with 2,5µM and 5µM LGK974. 
 
The expected inhibitory effect was detected in the 4T1 cell line with LGK974 (Fig 25). 
LGK974 were able to decrease 4T1 invasion in a dose-dependent manner (**p<0,01, 
***p< 0,001). Surprisingly, LGK974 did not significantly inhibit invasion of the cell lines 
410.4 or E0771LG. These results indicate that additional activities of the inhibitor beyond 
the Wnt pathway are possible. Therefore, further experiments were performed to prove this 
indication and to increase the N numbers. However, LGK974 was effective at a 
concentration of 5µM. To prove whether this effect is an inhibitory effect of the Wnt 
pathway needs to be investigated.  
 
3.3.3 CAM assay with LGK974 treatment 
In order to confirm the inhibitory effect of LGK974 on Wnt signalling and therefore an 
effect on colonization of tumour cells independently, Chorioallantoic Membrane Assays 
(CAM) were performed (Murphy, 1913). Cancer cells or cancer cells pre-treated for 24 
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hours with LGK974 were placed on the developing embryo of a chicken egg, on a special 
membrane. In case of 410.4, 3×10
6
 cells were re-suspended in 40µl ECM and then placed 
directly on the membrane. Additionally 1x10
5
 of 4T1 cells and 1x10
4
 E0771LG cells 
respectively were re-suspended in 40µl ECM and placed on the membrane. In this step, the 
different cancer cells or cancer cells pre-treated with LGK974 were placed on the 
membrane. Afterwards, eggs were covered with Leukosilk S and incubated for another 
seven days. Then, Leukosilk was removed and the membranes with the tumours were 
prepared and analysed. Tissues were fixed in PFA and sectioned. HE staining was 
performed in order to locate the tumour on the membrane. 
 
Fig 26: Effect of LGK974 by CAM assay. 
(A) Example for CAM assays, tumours of 410.4 cancer cells are shown (control) and (B) tumours 
of LGK974 treated 410.4 cancer cells. 
 
The histological sections of the CAM assays indicate differences between the tumours of 
the control group compared to the treatment group. A typical example is shown in Figure 
26. The amount of the tumour cells in the control group compared to the tumour of the 
treatment group was decreased. Also, in most cases tumours of the treatment group seemed 
significantly enlarged. It can be speculated, that in cancer cells stimulated with LGK974 
tumour cell colonization might be increased. In order to prove this finding, all sections 
were scanned by Image Scan and analysed with the basic software Image Scope. The 
tumour sizes of each scanned section were measured and tumours of the control group 
were compared with tumours of the treatment group.  
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Fig 27: Tumour enlargement by CAM assay. 
(A) CAM assays of cancer cell lines 410.4, (B) 4T1 and (C) E0771LG were shown. All tumour 
sizes of the control group were compared to tumour sizes of the treatment group. Error bars show 
SD, values, statistics sign was tested using unpaired, two tailed students t-test.  
 
Quantitative analysis of the HE stained sections revealed that tumours derived from the 
cancer cell line 410.4 treated with LGK974 (n=7) were significantly increased compare to 
the control group (n=9) (p=0.0149) (Fig 27A). This result verified the suggestion that the 
Porcupine inhibitor LGK974 support tumour cell colonization. However, tumours derived 
from cancer cell line 4T1 treated with LGK974 (n=7) were not significantly different in 
comparison to the control group (n=3) (p=0.4297). Also, the tumours derived from 
E0771LG (n=8) were not significant different to the control group (n=5) (p=0.5019).  
The effect of LGK974 needs to be clarified for a better understanding of this process. 
However, tumours developed from cancer cell line 4T1 or E0771LG treated with LGK974 
show no significant differences compared to the control group (Fig 27B and C). In case of 
4T1, the control group contained only a low number of samples (n=3) (Fig 27B). In order 
to investigate and prove the results, the number of CAM assays need to be increased and 
quantitative analyses of the tumour size need to be further improved to measure the exact 
sizes of the whole tumours. Furthermore, proliferation and angiogenesis need to be 
investigated; other histological staining for such markers will properly reveal further 
differences between these tumours in future studies.  
 
3.3.4 In vivo model with LGK974 treatment 
The established syngeneic mouse models for cerebral colonization of 4T1 and EO771LG 
were used to transfer the in vitro findings to an in vivo model. 
First, in order to use a non-toxic effective dose of LGK974, based on the study of Liu et 
al., we used a dose of 3mg/kg body weight (Liu et al., 2013b). Next, the application 
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method of LGK974 was tested in a pre-study as part of this work. These results were used 
to design a schedule (Fig 28). In order to do so, behaviour test were performed and mice 
were pre-treated with 3mg/kg body weight for five days with LGK974 (treatment group) or 
H2O (control group). For the application of LGK974, or H2O, gavages were used. 
Afterwards, mice were injected intracranially with the respective cancer cell lines. Mice 
were not treated on the day of surgery, or the day following surgery. Mice were weighed 
on the day of surgery and on recovery days, the day following surgery was the recovery 
day. Then, H2O or LGK974 was applied for another 35 days or until neurological 
symptoms became apparent. The weight of each mouse was measured daily. For a control, 
mice were pre-treated and treated with the same volume of H2O compared to LGK974, 
which was 50-60µl depending on the weight of the mouse.  
 
 
Fig 28: Schedule of experiment performance. 
Day -5 to -1 (five days) pre-treatment with LGK974 or H20 was performed. Cancer cells were 
intracranially injected on day 0. The day after surgery was the recovery day. Day 1 to day 35 
(35days) mice were treated with H20 (control group) or LGK974 (treatment group), followed by 
the observation of survived mice. 
 
First BalbC mice were pre-treated with 3mg/kg body weight LGK974 in the treatment 
group and with H2O additional for the control group over XY days (d-5 to d-1 before 
stereotactical injection d0). At day 0, mice were injected intracranially with 1x10
3
 cancer 
cells of 4T1. In a second experiment, mice were injected with a lower number of the 
cancer cell line 4T1 (1x10
2
). The survival of these mice is shown in Figure 28A-C as a 
Kaplan Meier diagram. In the following experiments (Fig 29 and Fig 30), H2O and 
LGK974 were applied daily for 35days accompanied with daily observation and weight 
measurements. Hanging wire and Rotarod test were performed as an additional indicator 
for developing cerebral metastasis. Mice with abnormalities in motor function or neuronal 
deficiencies as well as a weight loss of >20% were dissected immediately. Furthermore, 
every mouse was listed by age, injection date and dissection date and survival curves were 
calculated.  




Fig 29: Kaplan Meier surviving curves after cancer cell line 4T1 injection and LGK974 
treatment. 
(A) Survival curves of 1x10
4
 or (B) 1x10
3
 injected 4T1 cancer cells with LGK974 treatment or 
additional in controls. (C) Survival curve of both experiments together ((A)+(B)) to increase the 
numbers of animals.  
 
After the injection of 1x10
4 
cancer cells of 4T1, all mice in the LGK974 treatment group 
(n=15) developed metastasis that were significantly more aggressive than in the control 
group (n=15) based on both size of the metastasis and survival of the mice (p=0.0334) (Fig 
29A). Even after the injection of 1x10
3
 cancer cells of 4T1, all mice treated with LGK974 
(n=8) developed metastasis within 21days (Fig 29B). In the control group (n=5) mice 
developed metastasis on average later and one mouse even survived until the end of the 
experiment. Differences between the treatment group and the untreated control group were 
significant (p=0.0292). The OS of mice injected with cancer cell line 4T1 and treated with 
LGK974 of both experiments together (Fig 29A and 29B) was significantly decreased 
compare to the control groups (p=0.0072) (Fig 29C). 
The next experiment was performed with the cancer cell line E0771LG. Here, C57BL/6 
mice were pre-treated for five days with H2O or 3mg/kg body weight LGK974 were 
injected intracranially with 250 cancer cells of E0771LG (Fig 30).  
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Fig 30: Kaplan Meier surviving curves after E0771LG cancer cell injection and LGK974 
treatment.  
Survival curve of 250 injected E0771LG cancer cells with LGK974 treated or additional control 
(n=9 in control and treatment group). 
 
After the injection of 250
 
cancer cells of E0771LG, all mice in the LGK974 treatment 
group (n=9) developed metastasis. Also, all mice in the control group (n=9) development 
metastasis. Unfortunately, there was no significant difference on survival between the 
treatment and control group (p=0.2425) (Fig 30). These results did not confirm the idea, 
that LGK974 underlines the results of the CAM assays and do not prevent tumour cell 
colonization, despite, in vitro studies showed an inhibitory effect of LGK974 on Wnt 
signalling.  
To test if colonization of the tumour cell resulting in metastasis were different, tissue 
sectioning and HE staining were performed next. 
 
 
Fig 31: HE staining on control vs. LGK974 treatment sections. 
Representative examples of developed (A) metastases after injection of cancer cell line 4T1 vs (B) 
4T1 with LGK974 treatment. 
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HE staining was performed on sections, however, no obvious differences in the metastasis 
could be detected microscopically at first glance. Therefore the effect of the Porcupine 
inhibitor in terms of limitation of survival in vivo could not be investigated with HE 
staining. 
Remarkably, the injection of the cancer cell line E0771LG and treatment of LGK974 had 
no effect on the survival (Fig 30). After HE staining of sections derived from respective 
metastasis also no obvious differences were detectable. The reason for this might be a 
different growth rate and colonization behaviour of tumour cells resulting in metastasis 
developed from E0771LG cell line compared to metastasis developed from 4T1 cell line 
and suggests that LKG974 has no effect on fast colonizing tumour cells. 
To gain more information about the role of LGK974 on Wnt signalling and colonization of 
tumour cells, we analysed selected brain tissue from mice injected with 4T1 cancer cells 
for their gene expression levels of EMT markers and their Wnt profile. First, to 
characterise the epithial charcater of metastasis, Ecad and Vimentin were analysed by 
qRT-PCR. Brains were separated into two halves, the injected side of the brain (i.) and the 
non- injected side (n.i.). Both sides were compared to each other and the control group was 
compared to the treatment group (Fig 32). 
In this study it was shown that indeed LGK974 inhibits Porcupine, which leads to changes 
in Wnt secretion (Fig 24). Consequently, gene analyses on the Wnt pathway were also 
performed. The injected (n=12) and the non- injected sides (n=12) of the control group 
were compared and the injected (n=12) and the non- injected (n=12) sides of the LGK974 
treatment group were compared (Fig 32). Both, the injected and the non- injected 
hemispheres of each group were then compared to the respective other group, either 
LGK974 treatment group or non-treatment control group. Based on previous analyses 
(3.3.1), we measured the Wnt family members, which were expressed in the breast cancer 
cell lines, Wnt5a, Wnt5b, Wnt7a, Wnt6 and Wnt10a as well as the target of the LGK 
inhibitor, Porcupine. 
 




Fig 32: Analyses of developed metastasis from cancer cell line 4T1. 
(A) Ecad and Vimentin were evaluated to prove changes in epithelial or mesenchymal character of 
the cell line in metastasis (GOI = gene of interest, HK = housekeeper). (B) Wnt profile was used to 
detect eventual changes in the Wnt profile after LGK974 treatment (GOI = gene of interest, HK = 
housekeeper). Error bars show SD, values, statistics sign was tested using unpaired, two tailed 
students t-test. In all, expression of Ecad or Vimentin and Wnt analyses, 4T1 injected brains (4T1 
CTL i.) were compared to 4T1 injected brains with LGK974 (4T1+LGK974 i.) treatment. 
Additionally, 4T1 brain tissues of the non- injected side (4T1 CTL n.i.) were compared to 4T1 
brain tissues with LGK974 treatment of the non- injected side (4T1+LGK974 n.i.). The LGK974 
treatment group (4T1+LGK974 i/ni) were compared with the control group (CTL i/ni).  
 
These experiments did not support the notion that metastasis derived from the cancer cell 
line 4T1 - that had been treated with LGK974 - underwent EMT and MET. No differences 
in the epithelial (Ecad) or mesenchymal (Vimentin) character of the metastasis developed 
from 4T1 cell line were detectable when the treatment and the control groups were 
compared (Fig 32A). Furthermore, the inhibition of LKG974 on Porcupine and Wnt 
secretion could not be confirmed in the metastasis.  
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In the next step we investigated various Wnt ligands to test if they showed changes in the 
Wnt profil after the treatment with LGK974. We were not able to detect any significant 
differences in expression levels of Wnt5a, Wnt5b, Wnt6 or Wnt10a in the issue samples 
(Fig 32B). However, Wnt7a was significantly increased in the non- injected side after 
LGK974 treatment in comparison to the injected side (p=0.0021) (Fig 32B). Also, Wnt7a 
was increased in the non- injected side of the control group compare to the injected side of 
this group (p=0.0108) (Fig 32B). The expression of Wnt7a was increased in the injected 
side of the treatment group compared to the injected side of the control group, however the 
difference was not statistically significant (p=0.1087), (Fig 32B). Also, the expression of 
Wnt7a was not significantly increased in the non- injected side of the treatment group 
compared to the non- injected side of the control group (p=0.0050) (Fig 32B). 
Interestingly, the cancer cell line 4T1 expresses high levels of Wnt7a. However, metastases 
developed from 4T1 showed reduced expression levels of Wnt7a. Nevertheless, metastasis 
developed within 4T1 treatment group showed significant differences in their Wnt7a 
expression levels between the non- injected and the injected sides. The Wnt7a expression 
was significantly reduced in the injected side compared to the non- injected side, in both, 
treatment group and control group. We demonstrate that LGK974 might have an effect on 
Wnt7a expression by inhibiting Porcupine in metastasis derived from the 4T1 cell line or 
changing the composition of the metastatic cells and their microenvironment. To further 
elaborate on this interesting hypothesis and also to investigate EMT and MET on tumour 
cell colonization in greater detail, other markers for EMT and MET, e.g. those for specific 
transcriptions factors need to be established.  
Unexpectedly, the survival of the LGK974-treatment group was significantly decreased 
compared to the control group in the 4T1 trials. Therefore, it was suggested, that LGK974 
might induce EMT and MET thereby triggering tumour cell colonization and boosting the 
metastatic potential of these cells. However, Ecad and Vimentin were not regulated as 
indicators for EMT or MET. Therefore, we could not demonstrate that LGK974 induced 
EMT and MET yet.  
Suggestions that LGK974 impacts on Wnt signalling and that Wnt signalling could induce 
transcriptional changes, thereby driving EMT and MET need to be followed up. 
Consequently, additional EMT and MET markers need to be investigated. Therefore, we 
stimulated the cancer cell line 4T1 for 24hour and 48hours with LGK974. The 
unstimulated cancer cell line 4T1 was used as a control (Fig 33).  
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Fig 33: Expression level of EMT and MET markers of cancer cells +/- LGK974. 
(A) Ecad and Vimentin and (B) Twist2, Twist1, Snail, ZEB1, ZEB2 and expression of cancer cell 
line 4T1, 4T1 treated for 24hours with LGK974 and 4T1 treated for 48hours with LGK974 (GOI = 
gene of interest, HK = housekeeper). Error bars show SD, values, statistics sign was tested using 
unpaired, two tailed students t-test.  
 
After stimulating the cancer cell line 4T1 with LGK974, there were no significant 
differences in the epithelial (Ecad) or mesenchymal (Vimentin) characters of the 4T1 cell 
line treated with LGK974 compared to the control (Fig 33A). However, the expression of 
Twist2 was significantly increased, compared to the untreated control (Fig 33B). 
Furthermore, the stimulation with LGK974 for 48hours (p=0.0196) was more effective 
compared to that for 24hours (p=0.0329) revealing a time dependent effect of the 
treatment. However, for all other tested transcription factors relevant for EMT and MET, 
no significant differences are shown when 4T1 was stimulated with LGK974. This 
experiment needs to be repeated using higher N number and more time point’s stimulation. 
However, the preliminary data show significant differences in the expression of the 
transcription factor Twist2 after stimulation with LGK974 and the other data indicate the 
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possibility that the cancer cell line 4T1 underwent EMT and MET after treatment with 
LGK974. In the future gene expression analyses of the brain tissues from LGK974-treated 
mice might confirm this suggestion. 
In a brief summary, we found that the brain microenvironment reacts against the 
colonization of secondary malignancies, which has consequences on therapeutic strategies 
such as the application of drugs and the precise manipulation of important cancer 
pathways.  
 
3.3.5 In vivo model with LPS 
When we realized that interfering with the Wnt signalling by inhibiting Porcupine had 
unexpected treatment effects we searched for alternative treatment strategies. In our 
previous in vitro coculture-experiments we found that switching microglia into an acute 
inflammatory phenotype lead to improved treatment results. In brief, microglia-induced 
invasion was significantly reduced by treatment with Lipopolysaccharide (LPS) in 
modified Boyden chamber experiments (Pukrop et al., 2010b). To further elaborate on 
these in vitro findings the established syngeneic cerebral metastasis mouse model is ideal. 
First steps into this direction have already been performed as part of this study. Brain 
tissue from previous experiments - were we tested the right amount of cells for the 
metastatic potential (3.2.1) - was used for the gene analysis of immune-related markers. To 
investigate the impact of the immune response on tumour cell colonization, GFAP, CSF1 
and CSFR1 were used as markers for inflammation (Fig 34B-D). Additionally, CK8 was 
used as a marker for colonized tumour cells (Fig 34A). In case of the control group, ECM 
and medium were injected, and animals were sacrificed at the same time the last mouse of 
the group with injected cancer cells was sacrificed. Injected and non- injected side of the 
control or injected cancer cell group were compared. Additionally, the injected side of the 
control was compared to the injected side of the cancer cell group. Also, the non- injected 
side of the control group was compared to the non- injected side of the cancer cell group.  
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Fig 34: Analyses of developed metastasis from cancer cell line E0771LG. 
(A-D) The gene analysis was performed with three control samples and seven samples of the 
injected cancer cell line. Injected side of control (CTL i.) was compared to the control non- injected 
side (CTL n.i.). Injected side with E0771LG (E0771LG i.) was compared to the non- injected side 
of E0771LG (E0771LG n.i.). Control group was compared E0771LG group. Cancer cell line 
E0771LG was used and compared with the tissue (GOI = gene of interest, HK = housekeeper). 
Error bars show SD, values, statistics sign was tested using unpaired, two tailed students t-test. (A) 
CK8 was evaluated to prove the presence of colonized tumour cells. (B) GFAP as a marker for 
astrocytes was used and CSF1 (C) and CSFR1 (D) were used as marker for microglia cells.  
 
Consistent with the notion that colonized tumour cells express CK8 compared to the 
normal brain tissue, CK8 was significantly increased after cancer cell injection compared 
to controls (p=0.0014), (Fig 34A). The control, which was injected with ECM/medium 
showed significantly lower amounts of CK8. Interestingly, also the non- injected side of 
the cancer cell injected group, showed high levels of CK8, which was significantly 
increased compare to the non- injected side of the control group (p=<0.0001), (Fig 34A). 
However, the injected side showed significantly more CK8 expression as compared to the 
non- injected side (p=0.0206), (Fig 34A). The latter finding further underlined the previous 
finding that cells can disseminate also to the other, non-injected hemisphere 
Moreover, there was a significant increase of GFAP after the injection of E0771LG on the 
non-injected side in comparison to the non- injected side of the control (p=<0.0001), (Fig 
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34B). GFAP was significantly increased in the injected side of the control compared to the 
non- injected side (p=0.0258). GFAP was also highly expressed also in control brain 
tissue. Possibly, because of the high expression levels of GFAP in these samples, small 
differences in gene expression could not be discerned. However when we looked at the 
expression levels of CSF1, differences between the cancer cell-injected side and the non-
cancer cell-injected side were significant (p=0.0178), (Fig 34C). These results suggest that 
the injection of cancer cells activates microglia. However, analyses of CSFR1 could not 
confirm this conclusion (Fig 34D). Here, significant differences were only shown between 
the non- injected side of the control group and the non- injected side of the cancer-cell 
injected group, but not between the injected sides of both groups. These results could not 
demonstrate significant differences on the presence of microglia or astrocytes between 
control group and the cancer cell-injected group and further experiments are necessary 
including higher N numbers. However, sections stained against markers for microglia and 
astrocytes clearly show the presence and localisation of microglia cells (Fig 35A) or 
astrocytes (Fig 35B). It might be interesting to monitor the activation state of microglia, 
perhaps by having a closer look at their morphological appearance. 
 
Fig 35: Identification of immune reaction after injection of cancer cell line E0771LG. 
500 cells of cancer cell line E0771LG injected in the brain were immunologigally labelled with the 
macrophages/microglia marker IBA (A) and (B) with the astrocytes marker GFAP. The staining 
clearly showed the presence of microglia and astrocytes activation in the brain. Left side of the 
hemisphere=injected side, right side of the hemisphere= non- injected side. 
 
In comparison to the non- injected side, the injected side of these brains show a strong 
increased of activated microglia cells and astrocytes. Collected control brains, which were 
injected with ECM and medium alone, showed no expression of the immuno-markers (data 
not shown). It might be possible to use the stained sections in Fig 35 at higher 
magnification to analyse a possible morphologically detectable interaction between 
colonized tumour cells and immune cells in the future. 
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The effect of LPS had been tested in our group before and a dose of 1µg/µl was 
determined to be non-toxic for the E0771LG cancer cell line. These results can now be 
confirmed in the background of this syngeneic mouse model, using - in a first step - the 
E0771LG cancer cell line. 
Mice were injected intracranially with an amount of 500 E0771LG cancer cells as 
described before. For the treatment group 1µl of LPS was added to the mix of 
cells/medium/ECM. The control group was injected with cells/medium+1µl/ECM. 
Behaviour tests were performed before and after surgery and used as an indicator for the 
developments of metastases (Fig 36). 
 
Fig 36: Kaplan Meier surviving curve after E0771LG cancer cell injection +/- LPS. 
C57BL/6 mice were injected with cancer cell line E0771LG and treated (n=27) or not treated 
(n=28) with LPS. The survival of mice injected with E0771LG was significantly decreased 
compare to the survival of treatment group.  
 
All mice of the control group died within 50days. Surprisingly, mice treated with LPS 
were identified as long-term survivors. The surviving prognosis for the treatment group 
was significantly (p=0.0090) increased with 40% survival and no more mice from this 
group died within the next month when the experiment was stopped. These first results 
gained with this model indicate that LPS has a positive treatment effect (Fig 36). 
Specifically, LPS was shown to activate the immune response by activating the Toll-like 
receptor pathway. Especially, TLR4 is responding to LPS (Regen et al., 2011). Moreover, 
TLR4 signals in a MyD88- and TRIF-dependent way, adaptor molecules that are specific 
for the TLR signalling pathway (Hagemann et al., 2008). This indicates that two adaptors 
in TLR signalling, MyD88 and TRIF, which are responding differently to LPS, may 
regulate tumour progression via different mechanisms. MyD88 was shown to play a role in 
promoting metastasis, which was driven by macrophages. In order to investigate the role of 
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MyD88 and TRIF and the TLR signalling on tumour cell colonization, we designed 
experiments for an in vivo study. Three groups of mice were used to compare the survival 
prognosis with or without LPS treatment. WT mice, MyD88 knockout mice and TRIF 
knockout mice were intracraniallay injected as described before, with 500 cancer cells of 
E0771LG or 500 cancer cells of E0771LG and LPS. 1µl (1µg/µl) of LSP was added to the 
mixture of cells, medium and ECM. All mice and the respective cancer cell line E0771LG 
have a C57BL/6 background, which allows us to use them as a syngeneic mouse model for 
further analyses. Behaviour tests were performed before and after surgery and used as an 
indicator for metastasis development.  
 
Tab 12: Mean survival of different mice strains and +/- LPS treatment 













19  29  2.027  



















WT mice injected with the cancer cell line E0771LG and LPS survived much longer than 
all other tested mice here (Tab 12). In WT mice the protective effect of LPS could thus be 
confirmed. WT mice injected with the cancer cell line E0771LG and LPS (n=35) survived 
significantly longer than mice injected with E0771LG alone (n=33) (p=0.0179). MyD88 
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knockout mice injected with the cancer cell line E0771LG (n=12) or E0771LG and LPS 
(n=15) showed a slight difference regarding their survival (p=0.2200). However, here LPS 
showed no protective effect, the effect of LPS seems to have an adverse effect in Myd88 
knockout mice. The injection of TRIF knockout mice with the cancer cell lines E0771LG 
(n=12) or E0771LG and LPS (n=13), revealed no differences on survival (p=0.9382) 
either. These first preliminary results indicate the importance of Myd88 and TRIF for the 
protective effect of LPS and showed differences between MyD88 and TRIFF. In order to 
investigate the protective effect of LPS via TLR signalling in greater detail, available brain 
tissue from all experiments can be used for further analysed.   
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4 Discussion 
4.1 Characterisation of different cancer cell lines  
It is well accepted that not the primary tumour of breast cancer but its metastasis is the 
main cause of death in these patients. Until now has not been possible to safely predict the 
risk of metastasis development of the individual patient. Therefore, great efforts have been 
made the last decades to identify for example by gene-expression signatures of the primary 
breast cancers (Weigelt et al., 2005) prognostic markers to better predict the individual risk 
for metastasis. However, this is still not recommend for the daily routine to use this as 
decision instrument. Moreover, the manifestation of metastasis e.g. in the brain is not 
predictable. In order to detect metastatic tumour cells seeding specifically the brain, 
markers on (circulating) tumour cells were analysed in vivo experiments (Bos et al., 2009). 
One method others tried to investigate the CTCs, was the identification by Cytokeratin 
expression. In breast cancer CK8, CK18, CK5 and CK17 were typically expressed and 
therefore potential suitable markers to study successful colonization of breast cancer cells 
in the Cytokeratin negative brain tissue (Perou et al., 2000). In order to transfer these 
findings of the human studies to an experimental design for mice, first, we characterised 
available murine breast cancer cells in terms of their relevant gene expression levels. We 
identified typical characteristic markers of these cell lines and measured significant CK8 
expression in all murine breast cancer cell lines. So, CK8 gene expression was an ideal 
candidate to quantify the breast cancer metastatic load in the negative brain parenchyma. 
In the next step, we wanted to better understand biological process. Therefore, we first 
focused on EMT markers which have been demonstrated that these factors facilitate 
metastasis development and their expression in the primary tumour are correlated with 
poor prognosis (Thiery, 2002). Consequently, we analysed EMT markers on available 
murine breast cancer cell lines, which were differently expressed in the respective breast 
cancer cells. The hypothesis was now, that these features should influence the cerebral 
colonization capacity of three murine breast cancer cell lines.  
 
It was shown that activated Wnt signalling promotes EMT-like phenotypes in breast cancer 
cells (Wu et al., 2012) and Wnt signalling was also shown to play an important role in the 
cerebral metastatic process (Pukrop et al., 2010b) (Klemm et al., 2011) (Smid et al., 2008). 
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To confirm the role of Wnt signalling in cerebral metastasis development, we characterised 
the murine breast cancer cell lines with respect to their Wnt profile. The qRT-PCR and 
protein measurements revealed high expression levels of Wnt5a in the cancer cell line 
E0771LG, while high expression of Wnt7a was detected in the cancer cell line 410.4 and 
4T1. Our available cancer cells were later used to study the role of glia contact to 
colonized tumour cells in an in vivo model. Taken together, in the first step we 
characterised the murine breast cancer cells for their epithelial and mesenchymal character 
and Wnt profile bases for our further investigations in the functional in vitro tests and 
finally in vivo experiments. Importantly, the profiles of the murine cells were already 
detected in human breast cancer samples (Huguet et al., 1994b) (van de Vijver et al., 2002) 
(Perou et al., 2000). 
 
4.2 Establishing of an in vivo syngeneic cerebral metastasis model 
The impact of the tumour microenvironment in the primary tumour got more and more 
impact on outcome of the disease. We and others also described that the metastatic 
microenvironment has also significant impact on many features of the pre-metastatic cells 
seeded the distant organ, in particular the brain (Pukrop et al., 2010b) (Chuang et al., 
2013). However, the majority of the in vivo studies are performed in Xenograft models, 
which systematically exclude or at least massively influence this very important force 
during metastasis in comparison to the human situation. 
Thus, firstly only an immune-competent model reflects the real impact of the metastatic 
microenvironment and secondly is applicable for studies of immune-based therapeutic 
strategies. Moreover, it has been demonstrated, that the genetic background from which 
cancer arises also has an effect on the capacity of mouse mammary cancer cells to 
metastasis
 
and support the hypothesis that the genetic make-up of the host and background 
of the cancer cells need to be similar (Lancaster et al., 2005). With this knowledge our 
main goal was to establish a syngeneic cerebral metastasis mouse model to investigate 
colonization and involved interaction of the metastatic microenvironment. This is at least a 
prerequisite to develop new therapeutic targets in both, “seed and soil”, which might lead 
then to more successful intervention strategies for breast cancer metastasis. 
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Mammary fatpad of syngeneic mouse models injected with the cancer cell line 4T1, which 
originally derive from a spontaneous mouse mammary primary tumour of a BALB/C 
mouse, metastasise to the brain and therefore metastatic outgrowth can be studied 
(Aslakson and Miller, 1992a). Not all of our cancer cell lines are able to metastasize 
spontaneously. Therefore, we injected cancer cells intracranially considering the 
background of these cells and mouse strains. Very importantly, we used cancer cells that 
were embedded in extracellular matrix (ECM) before applied to the brain.  
Different types of cancer cells tested to develop metastasis here were used for further 
experiments and the establishment of in vitro markers. Importantly, all cell lines were able 
to develop metastasis caused by various amounts of injected cells and their colonization 
patterns. Interestingly, we found different infiltration patterns of the cancer cell lines. The 
cancer cell lines 410.4 and 4T1 showed cohort infiltration, whereas the cancer cell line 
E0771LG showed diffuse infiltration. Based on personal communication with L. Siam 
(manuscript on preparation), we know that those different infiltration patterns are relevant 
for the OS in patients with cerebral metastasis. Those patients with no infiltration have a 
much better prognosis than patients with cohort or diffuse infiltration. With this finding, 
we are able to investigate the biological consequence of the infiltration of the adjacent 
brain parenchyma. Until know, these features are not addressed at all.  
Quantification of the developed metastasis of cancer cell lines was performed with the 
marker CK8. Interestingly, an important finding was observed when CK8 was used to 
detect colonized tumour cells (Fig 30A). Unexpectantly, we found colonized tumour cells 
also in the non- injected side (other hemisphere of the brain) derived from the injected 
cancer cells. This finding indicates that the into the benign brain parenchyma infiltrating 
carcinoma cells are not only a surrogate parameter for worse OS but also a potential source 
for further metastasis in complete other regions of the affected organ. This would mean 
those established metastases are a potential source for new metastasis, at least in the same 
organ. Taken together, this is one of the very few in vivo results demonstrating that 
metastases metastasize.  
  




Fig 37: Colonized tumour cells are able to disseminate. 
Colonized tumour cells perform metastasis. These cells can disseminate in the brain. 
 
So far we have identified different colonization patterns of metastatic cells. However, 
systematically analyses should be performed to further quantify the infiltration and new 
breast cancer colonies of the disseminated cells. Additionally, the amount and patterns of 
the affected menigeal and ventricles should also be measured. Therefore, we cooperate in 
future with Trevor Do, a group member of the research group at STTARR in Toronto, who 
routinely uses an analysing software which could measure these features. 
Further, we might be also able to identify the different zones of the metastatic tissue and 
there cellular composition. We therefore aim to investigate the astrocytes, microglia and 
immune responses in the core of the metastasis, at the interface to the benign brain 
parenchyma and infiltration zone. This is of major interest because we already see 
significant differences of at least the astrocytes and microglia, which accumulate at the 
interface. However, we detected differences in respect to the syngeneic models. For 
example, astrocytes and microglia were detectable around the metastasis of all injected 
cancer cell lines, but in case of cancer cell lines 4T1 and E0771LG also between the 
metastatic cells. Gene expression analyses also indicate differences in the three models. 
Further, we were able to quantify colonized tumour cells with CK8. Hence, we conclude 
that in terms of infiltration patterns of the carcinoma cells and the response of the brain 
tissue varies in dependency of the features of the carcinoma cells. Some features, in 
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particular the infiltration patterns of the carcinoma cells, might be related to differences in 
gene expression based on the role of EMT and MET in tumour cell colonization and 
metastasis development. Therefore, EMT and MET markers should be further investigated 
as EMT and MET changes can potentially be used for new therapeutic strategies. In 
summary, we established four syngeneic cerebral metastasis mouse models to study the 
colonization of the brain and the resulting response of the brain microenvironment against 
the metastatic progression, which can now be used for further experiments and intervention 
studies. 
 
4.2 Clinical applications 
Breast cancer metastasis indicate a poor survival prognosis due to limited treatment 
options and the lack of proven effectively targeted therapies. Recently new therapeutic 
strategies focused on the inhibition of the Wnt signalling pathway have been developed. 
One of these novel promising treatment strategies for Wnt manipulation might be the 
Porcupine inhibitor LGK974 of Novartis.  
Currently this inhibitor is in use in clinical Phase 1 trial in advanced cancer patients. The 
idea was that LGK974 might be a useful novel drug for the treatment of Wnt dependent 
cancer progression. Therefore, patients with triple-negative breast cancer have been also 
included in this study. Excluded from this study were patients with brain metastasis that 
had not been adequately treated. Novartis evaluated in cell-based models that LGK974 
inhibits the Wnt pathway by specifically binding Porcupine, a membrane-bound O-
acyltransferase that catalysis the palmitoylation of Wnt ligands and functions on Wnt 
secretion. Furthermore, in preclinical studies they found that inhibition of Porcupine with 
LGK974 is associated with anti-tumour activity. 
(http://www.novartisoncology.com/ct/pipelineDetails?compound=LGK974&diseaseAcr=B
C) 
This was confirmed by a study by Liu et al. (2013a). They showed the successful use of 
LGK974 as a potent, selective, and orally bioavailable Porcupine inhibitor on the initiation 
and development of primary tumours. This in vivo study demonstrated on a Wnt dependent 
murine breast tumour model (mouse mammary tumour virus-driven Wnt1 model), that the 
inhibition of Wnt signalling at well-tolerated doses is associated with a reduction of 
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tumour growth. In our study we investigated a tolerable dose of LGK974 in vitro and 
confirmed the effect of LKG974, to cause a reduced invasiveness of cancer cells in vitro, 
however, only for the cancer cell line 4T1 and with a positive trend in 410.4. However, this 
effect could not be confirmed for EO771LG cell line with the different Wnt profile, which 
mainly expresses Wnt5a. Therefore, these results indicate that the action of LGK974 might 
depend not only on Wnt secretion but also on a specific Wnt profile. We additionally 
detected differences in the inhibitory effect of LGK974 on the protein level using cancer 
cell lines 410.4, 4T1 and E0771LG. Interestingly, Wnt5a abolished in the cancer cell line 
E0771LG treated with LGK974. In contrast, Wnt7a/b seemed to accumulate in the cytosol 
of the cancer cell lines 410.4 and 4T1 as expected by the mechanism of action of the drug. 
Thus, this indicates that the inhibition of Porcupine can have different effects on Wnt 
proteins levels that might also depend on the type of the cancer cells. However, it could 
also be a technical effect when the missing palmitoylation of Wnt5a changes the tertiary 
form of Wnt5a, which could not be recognized by the antibody anymore. So, further 
analyses are required to explain why the cancer cell lines tested here react differently to the 
treatment with LGK974, which has potential therapeutic implications. Notably, Porcupine 
was investigated to be necessary for all of the Wnt pathways (Dodge et al., 2012) and as 
we detected an effect of LGK974 on both tested Wnts, we were able to confirm the Wnt 
inhibitory effect of LGK974. 
Next we proved effects of the LGK974 inhibition on Wnt signalling in vivo. The 
physiological conditions can have serious impacts and therefore it is important to address 
possible therapeutic treatment side effects on in vivo experiments. Therefore, we treated 
mice orally with LGK974 by using the established cerebral metastasis mouse models. 
Surprisingly, in further experiments on LGK974, we detected another effect of the 
inhibition of Porcupine with LGK974. In contrast to the in vitro experiments, the cancer 
cell line 4T1 in combination with LGK974 lead to a significant decrease of OS, 
independent from the amount of cancer cells that were injected in vivo. This effect was 
observed in all the in vivo experiments that were performed with the cancer cell line 4T1 in 
vivo. Also, this was confirmed via CAM assay where we found that cancer cells 410.4, 
with a comparable Wnt profile like 4T1, stimulated with LGK974 increased tumour cell 
colonization. The 4T1 showed the same trend, and more experiments have to be performed 
to underline this effect. However, in none of the functional and in vivo experiments we saw 
any treatment effect in the Wnt5a driven by EO771LG. So, our results significantly 
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underlined that Wnt ligand expression is not sufficient for treatment effects. Most 
important, here we demonstrate negative treatment effects in the 4T1 model. As described 
above, Liu et al demonstrated in their study a positive treatment effect of LGK974 in early 
stages of breast cancer. However, our model represents late stage of cerebral metastasis 
when the breast cancer cells colonized the brain tissue. Our finding demonstrates that 
biological treatments, which affect stem cell features or EMT, could lead in early stage in 
vivo models beneficial outcome but with an opposite effect on late stage tumour models 
(Fig 35). The conclusion of this study is that biological inhibitors seem to be not only 
dependent on the profile of the cancer cells but also stage dependent. 
 
 
Fig 38: Effect of LGK974 on primary tumour and colonized tumour cell. 
Treatment of LGK974 on primary tumour was successful but not on colonized tumour 
cells in a cerebral metastasis model. Most important, this biological treatment strategy 
could lead to progression of already seeded breast cancer cells in the distant organ while 
the primary tumour respond to the therapy and regress. Now, if seeding is really an early 
event in the process of metastasis, before diagnosis of the primary tumour, this finding 
have significant impact on all further treatment strategies affecting stem cell factors or 
EMT.   
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Remarkably, the injection of the cancer cell line E0771LG in combination with LGK974 
had no effect on survival. The reason for this might be Wnt dependent differences in the 
colonization capacity of tumour cells from cancer cell line E0771LG compared to 4T1. 
Cancer cells undergoing EMT and MET are capable of invasion, migration and 
proliferation and therefore promote tumour cell colonization. Recently, it was shown, that 
Wnt signalling induces EMT and MET (Qi et al., 2014),(Bo et al., 2013). The activity of β-
catenin as a cadherin-binding protein leads to a break of cell-to-cell adhesions built by β-
catenin and E-cadherin. An overexpression of E-cadherin and the reduction of 
mesenchymal markers leads to the downregulating of Wnt signalling (Schäfer et al., 
2014b). These findings also might explain our results: after injection of the cancer cell line 
410.4 metastasis development was much slower and subsequent demonstrated better OS 
compared to the injection of cancer cell line 4T1 or E0771G. Moreover, E-cadherin was 
highly expressed in metastasis developed from 410.4 compared to the other cancer cell 
lines used in this study, leading to suggest that high levels of E-cadherin in metastasis and 
corresponding cancer cell lines might give a better prognosis for survival. In contrast, loss 
of E-cadherin expression contributes to metastasis (Kalluri and Weinberg, 2009). Clearly, 
these circumstances need to be further analysed by investigating the interdependencies of 
Wnt signalling, EMT and MET by confirming that Wnt signalling is involved in tumour 
cell colonization and that Wnt can promote EMT and MET. To investigate the role of 
EMT and MET on tumour cell colonization in our model, transcription markers, e.g. Snail, 
Slug, ZEB1, ZEB2, Twist1 or Twist2, which are regulating EMT and MET, need to be 
investigated and analysed (Kalluri and Weinberg, 2009). 
Interestingly, Louie et al. (2013) found in the human breast cancer cell line MCF7, low 
levels of E-cadherin at the cell membrane and high levels of the transcription factor Snail 
in the nucleus, however, breast cancer cell lines selective to the brain showed low levels of 
E-cadherin and high levels of Snail, indicating that these cells underwent EMT (Louie et 
al., 2013). Furthermore, Wnt3a was found to promote the expression of the key 
transcription factor for EMT, Snail. Besides, Wnt3a increases metastasis (Qi et al., 2014). 
Hence, the microenvironment is important for the outcome of Wnt signalling and for EMT 
and MET. Consequently, we suggest, that LGK974 may lead to EMT and MET and 
therefore to tumour cell colonization and development of metastasis depending on the 
presence of activated, specific Wnt molecules in the microenvironment. The hypothesis 
that LGK974 impacts on Wnt signalling and that Wnt signalling could induce 
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transcriptional changes in order to drive EMT and MET should be followed up. In order to 
do this, the transcription factors Twist1, Twist2, ZEB1, ZEB2 and Snail need to be 
investigated. First in vitro experiments on this showed that cancer cell lines expressed 
different levels of transcription factors for EMT after stimulation of LGK974. Twist, was 
demonstrated to be upregulated in highly metastatic 4T1 cells but downregulated in non-
metastatic cells. Furthermore, Twist increased breast cancer metastasis by promoting EMT 
(Yang et al., 2004). The expression of the EMT and MET transcription marker Twist2 was 
significantly changed after treatment with LGK974 compared to the untreated control. 
Twist2 gene expression was increased after the stimulation with LGK974 leading to 
suggest, that LGK974 is increasing Twist2 expression and therefore EMT and MET. In 
order to prove this hypothesis, more experiments, with higher N numbers, need to be 
performed and confirmed on protein level. Further, developed metastasis of the cancer cell 
line 4T1 need to be analysed for their Twist2 expression patterns, to identify metastasis 
that are responsive to LGK974.  
The microenvironment was frequently investigated to play an important role in survival 
and growth of metastatic cells and the formation of metastasis (Quail and Joyce, 2013). 
Moreover, microglia cells were shown to be involved in tumour cell invasion (Lorger and 
Felding-Habermann, 2010). However, very little is known about the interaction between 
the brain environment and colonizing tumour cells. Interestingly, microglia activation was 
decreased in breast cancer cell lines selected from brain metastasis with a MET-like 
phenotype. By inducing an EMT-like phenotype in these cells, the number of activated 
microglia cells was increased (Louie et al., 2013). These findings underline close 
relationships between the immune response and metastatic formation by EMT. Moreover, 
it was shown that microglia cells in brain metastasis of breast cancers promote tumour cell 
colonization in human patients (Fitzgerald et al., 2008b). The therapeutic manipulation of 
the cytoprotective or cytotoxic response of microglia cells requires new targets and 
strategies to successfully interfere with tumour cell colonization in the brain. 
 
4.3 Immune response trigger by LPS and effects on cancer cell 
To investigate and manipulate the local defence system in the CNS and see the effects on 
tumour cell colonization, the established cerebral metastasis mouse model of the 
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EO771LG was used. In this study we have performed treatments with lipopolysaccharides 
(LPS) to stimulate locally the microglia response. 
However, before we started the intervention studies, we first proved by qRT-PCR that the 
glial cells and immune cells were activated after colonization of the cancer cell line 
E0771LG to the brain using the microglia markers CSF1 and CSFR1 and the astrocytes 
marker GFAP. Interestingly, CSF1 was significantly increased on the side that had been 
injected with cancer cells, compared to the non- injected side. This result indicates that 
microglia either reacted to the injection or to the presence of cancer cells. Furthermore, all 
markers were expressed in the control group where we injected only ECM. This result 
proved the presence of glia cells. However, control samples, showed no activated gene 
expression, especially, CSF1 and CSFR1 were not up-regulated despite the fact that mice 
underwent the same surgery as the cancer cell injected group. However, microglia and 
astrocytes staining clearly showed the absence of microglia and astrocytes in the control 
samples, but the presence and localisation in the cancer cell injected group. Nevertheless, 
we could not detect significant differences between control group and the cancer cell 
injected group in all analysed genes. Two reasons might explain this: In case of GFAP, due 
to the high expression levels of GFAP in these analyses it is possible that small differences 
could not be discerned. Secondly, only three control samples and seven samples with 
cancer cell injection were used until now. A higher N number of control samples need to 
be performed. Nevertheless, mice were sacrificed up to three weeks after the intracranial 
injection. The results showed expressions of all these genes, demonstrating the activation 
of glia cells in the presence of induced metastasis, while this glial activation might possibly 
be the cause of the injury during the injection (Loane and Byrnes, 2010). However, 
microglia and astrocytes staining clearly showed the presence and localisation of microglia 
cells and astrocytes in correlation with the injected side and the interaction with colonized 
tumour cells, which points to a colonized tumour cells-immune reaction. In comparison, 
the non- injected side of these brains showed a strong reduction of activated microglia cells 
and astrocytes.  
In summary, these results strongly suggest, that the observed glial activation is not merely 
triggered by the injury of the surgery. Thus, another advantage of our model is the 
presence of a non-injected control side that will prove helpful to address these questions 
during metastatic progression, as I have pointed out here. We could also quantify colonized 
tumour cells in the cancer cells injected brains with CK8. Furthermore, we can prove the 
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presence of microglia cells and astrocytes here. Therefore, this model can be used for 
further experiments addressing metastasis-immune related questions. 
LPS was recently shown to induce an immune response, which leads to the activation of 
microglia cells and astrocytes in the CNS (He et al., 2006b). Moreover, LPS-induced 
cytotoxicity on metastatic cancer cells were executed by microglia cells. This effect is 
dependent on time and concentration of LPS application. It was shown, that when using 
lower levels of LPS, cancer cells are insensitive to the microglial cytotoxicity. Therefore, 
apoptosis of cancer cells induced by microglia cells is dependent on the effect of LPS. 
Here, we wanted to investigate the role of LPS on tumour cell colonization as a potential 
trigger for the activation of glia cells in our newly established cerebral metastasis model.  
After the injection of cancer cells locally pre-treated with LPS into mice, their survival was 
highly significantly increased in comparison to the non LPS-treated group. These first 
preliminary results on survival indicate that LPS might have a protective effect, by giving 
an additional boost to the activation of microglia, and confirmed preliminary findings by 
Han-Ning Chuang (http://hdl.handle.net/11858/00-1735-0000-000D-F01F-7). She showed 
that LPS hindered microglia induced invasion of cancer cells, which was also confirming 
the study of He et al (2006). Furthermore, Wnt5a was shown to play an important role in 
tumour invasion (Pukrop et al., 2006). Han-Ning confirmed that Wnt5a expressed from 
microglia cells is essential for tumour cells to invade and colonize the brain parenchyma 
effectively. More experiments need to be performed for a better understanding of the 
colonizing behaviour of tumour cells and the role of microglia in this context. In order to 
do this, further analyses of the prepared brain tissue from the LPS experiment of our 
syngeneic cerebral metastasis mouse model can be performed. Immunstainings using, e.g. 
antibodies against GFAP and IBA might be useful to investigate the role of microglia in 
tumour cell colonization. Moreover, gene expression analyses can be performed to further 
test the role of Wnt in this context. In order to do this, brain metastasis tissue should be 
analysed for all established markers on the Wnt profile, shown here, as well as CSF1, 
CSF1R and GFAP. 
LPS was identified to activate microglia and cytokine induction by activating the Toll-like 
receptor (TLR) pathway, where TLR4 is responding to LPS (Regen et al., 2011). TLR4 is 
using the myeloid differentiation primary response gene 88 (MyD88) to drive 
inflammatory response. Another adapter is necessary for transferring TLR4 signalling, the 
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TIR-domain- containing protein (TRIF) (Kawai and Akira, 2009). The differences in the 
LPS response have been described as an early MyD88 depending response, which leads to 
the activation of nuclear factor-κB (NF-κB). Additionally, a later TRIF response to LPS 
leads to the late activation of NF-κB and to the induction of cytokines, chemokines, and 
other transcription factors (Mogensen, 2009). These findings demonstrate the different 
response of MyD88 or TRIF to LPS. 
Interestingly, MyD88 was shown to play a role in promoting metastasis (Hagemann et al., 
2008). Therefore, LPS activates TLR4 and signals in a MyD88- and TRIF-dependent way. 
This indicates that two adaptors in TLR signalling, MyD88 and TRIF, which are 
responding differently to LPS, may regulate tumour cell colonization via different 
mechanisms. By using microglia from Myd88 deficient mice, Han-Ning showed a 
reduction of microglia-induced invasion of cancer cells in her brain slices model. It can 
therefore be hypothesised that the adaptor MyD88 is required for tumour cell colonization, 
whereas the adapter TRIF causes the protective effects of TLR4 activation. Moreover, 
TRIF- and MyD88-deficient microglia can change the effects of LPS also on Wnt related 
genes, which also underlies the impact of MyD88 and TRIF on tumour cell colonization 
(http://hdl.handle.net/11858/00-1735-0000-000D-F01F-7). 
In order to further elaborate on these results and interpretations, the involved pathways in 
tumour cell colonization need to be investigated in more detail. Therefore, gene expression 
levels of MyD88 and TRIF need to be tested by using the prepared brain tissue from the 
LPS experiment. We suggest that high expression of MyD88 leading in tumour cell 
colonization and metastasis and high level of TRIF leading suppressing of tumour cell 
colonization. Moreover, there are several mouse strains available, e.g. MyD88 knockout or 
TRIF knockout mice and both models have a background strain of C57BL/6. These mice 
are ideal to address these questions in combination with the syngeneic mouse model by 
using the methods established here. In order to do this, the established cerebral metastasis 
mouse model of C57BL/6 should be used in combination with the cancer cell line 
E0771LG, which is derived from C57BL/6 mice. Interestingly, first own experiments 
showed that the application of LPS has no protective effect in a TRIF knockout mouse 
model, which is in support of the hypothesis stated above. TRIF knockout mice injected 
with the cancer cell line E0771LG with LPS treatment did not survive longer than TRIF 
knockout mice injected with the cancer cell line E0771LG without LPS treatment. This 
strongly indicates the importance of TRIF on the protective effect of LPS in tumour cell 
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colonization. In contrast, in the case of MyD88 knockout mice, we were not able to detect 
differences between MyD88 knockout mice injected with E0771LG without LPS treatment 
and MyD88 knockout mice injected with E0771LG with LPS treatment. However, in WT 
mice with induced metastasis in the absence of LPS survived a mean of 19days, while 
mice of the LPS treatment group survived almost a week longer. Thus, two independent 
metastasis mouse models with a disrupted TLR4-signalling pathway died earlier than WT-
controls, strongly suggesting that the protective effect of LPS requires intact TLR4 
signalling, in particular in microglia. 
This result demonstrates that TRIF and MyD88 are indeed necessary for the protective 
effect of LPS. Moreover, LPS application without intact MyD88 or TRIF-signalling even 
seems to have a detrimental effect on survival. We were able to address our established 
syngeneic cerebral metastasis mouse model to a different experimental design and could 
prove the protective effect of LPS in the WT mouse model. We supported in vivo the 
protective effect of LPS on breast cancer metastasis to the brain. 
In this study syngeneic cerebral metastasis mouse models were successfully established, 
which can be used to better understanding the role of the brain microenvironment on 
tumour cell colonization during different infiltration patterns. Furthermore, therapeutic 
treatment strategies claiming at the treatment of metastatic breast cancer can be applied 
using these different models.  
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5 Summary 
We characterised four murine cancer cells and investigated typical markers, which were 
similar to human cancer cells. We established syngeneic cerebral metastasis mouse 
models, methods to quantify the metastatic cancer cells in the brain parenchyma´s well as 
the metastatic capacity of these colonized tumour cells. We investigated the colonization 
behaviour of these cancer cell lines in vivo and demonstrated differences in tumour cell 
colonization and the reaction of the glia cells. Importantly, our results are consistent with 
human studies. Interestingly, we demonstrate that colonized tumour cells were able to 
further disseminate in the brain as source for new metastatic lesions. 
The Wnt profiles of the cancer cell lines were investigated and Wnt5a and Wnt7b were 
identified and provide the basis for targeting Wnt signalling for further experiments in the 
respective models.  
Furthermore, we investigate an effective dose of the Porcupine Inhibitor LGK974 in cell 
culture and prove the inhibitory effect of the LGK974 on Wnt secretion and functional 
effects on tumour invasion in vitro and could confirm previous findings of LGK974 on 
primary tumours. Moreover, we observed another effect of LGK974 and demonstrated that 
LGK974 appears to worsen the colonization in the 4T1 colonization model but not 
EO771LG. Therefore, the treatment of LGK974 on primary tumours seems to be a good 
treatment strategy, but not for metastatic cells. Also, the effects seem to be dependent on 
specific Wnt profiles. 
Additionally, we were able to address our established syngeneic cerebral metastasis mouse 
model to a different experimental design to investigate the role of microglia in tumour cell 
colonization. So far we could trigger an immune response with LPS and could prove the 
protective effect of LPS in the WT mouse model.  
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